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ABSTRACT 
 
It has been proposed that the Notch signalling pathway plays a key role in the 
pathogenesis of head and neck squamous cell carcinomas (HNSCC). It has also been 
shown that the sheddase, ADAM17, whose intracellular trafficking and subsequent 
maturation is dependent on iRhom2, is key in the activation of the Notch pathway at 
the cell membrane, leading to the release of an intracellular domain for downstream 
activities. This thesis investigates the levels and distribution of iRhom2 and ADAM17 
in HNSCC, and functional changes resulting from up-regulation of iRhom2 in HNSCC 
cell lines. 
Immunoblotting, using protein samples extracted from fresh, snap-frozen tissues (68 
HNSCC and 27 paired normal tissues), and probing for iRhom2 identified relatively 
high expression levels of this protein in 43/68 tumour samples compared to 5/27 
normal samples (p<0.05). Similar observations were obtained for ADAM17 
expression, with high expression in 27/68 tumour samples compared to 4/27 normal 
samples (P<0.05). A positive correlation was observed between levels of expressions 
of iRhom2 and ADAM17 in these tissues (though not statistically significant), but only 
iRhom2 expression correlated with patient survival (p<0.05). Non-correlation of 
iRhom2 expression with other clinicopathological features was perhaps due to the 
relatively small number of samples investigated. Using a different cohort of HNSCC 
tissues, we also assessed levels of iRhom2 and ADAM17 and their intracellular 
distribution using tissue microarray (TMA) approach. Western blot results could not 
be corroborated with this methodology, given that most of the tissues stained 
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negative for iRhom2, and 76/88 stained “highly positive” for ADAM17, with no 
observable specificity with ADAM17 staining pattern. Up-regulation of iRhom2 was 
achieved in the HNSCC cell lines, PE/CA-PJ15 and LIV37K; and in NOK (normal oral 
keratinocyte) cells and was, followed by shRNA knock-down of RHBDF2 (which codes 
for iRhom2). No observable differences were observed in the rate of cell replication 
when comparing wild-type, over-expressing and knock-down clones across each of 
the cell lines. However, a higher rate of cell migration was demonstrated in 
association with iRhom2 up-regulation, more in the HNSCC cell lines than the NOK. 
This higher rate of migration was shown to be reversed by the shRNA knock-down of 
RHBDF2, demonstrating that it is increased iRhom2 that is causative. Furthermore, a 
significant increase in the level of expression of mature ADAM17 was observed, 
following upregulation of iRhom2. 
iRhom2 and ADAM17 are both up-regulated in HNSCC, with up-regulation of iRhom2 
associated with increased cell migration and decreased patient survival. Further 
experiments should aim to address whether it is the increased ADAM17 expression / 
activity and / or Notch activity that is the downstream effector of the observed 
effects. If will be important to expand the cohort of samples and cell lines used for 
this study to further validate the present findings, while also optimising some of the 
aspects that have not achieved significant results.  
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1 CHAPTER 1: INTRODUCTION 
 
 
 
1.1 Introduction  
 
Current research is preoccupied with the molecular basis of cancer. A high proportion 
attempting to highlight specific biomarkers, targets for therapy and possible 
prognostic parameters. This study will investigate the possible role of the rhomboid 
protein, iRhom2 in the pathogenesis of oral cancers, particularly head and neck 
squamous cell carcinomas, with a focus on its proposed interaction with the 
sheddase, ADAM17. 
Specific mechanisms have been suggested in an attempt to unravel the remarkably 
complex process by which normal cells become transformed into cancerous or 
malignant variants or derivatives. These often focus on activities which result in 
 24 
 
alterations in four vital and overlapping cellular events – growth, proliferation, 
differentiation and cell death. The multistep process of carcinogenesis is proposed to 
lead to gradual and successive genetic changes ultimately leading to the acquisition 
of a “growth advantage” for the transformed cancer cells1. Eight survival capabilities, 
described as the hallmarks of cancer are common with virtually all cancer types. 
These survival capabilities enable cancerous cells adopt a new mechanism which 
works contrary to the original anticancer defence mechanisms possessed by healthy 
non-cancerous cells. They have been described as; self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion of apoptosis, limitless replication, 
sustained angiogenesis, tissue invasion/metastasis, reprogramming of energy 
metabolism and evading immune destruction2 (Figure 1.1). A sound understanding 
of the basic hallmarks of cancer is important in the development of effective 
anticancer therapeutic agents as well as in unmasking potential prognostic 
biomarkers.  
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1.2 The hallmarks of cancer 
 
 
 
Figure 1.1 Hallmarks of cancer:  
Top - Illustration of the initial six hallmark capabilities first proposed. Bottom – Latest 
additional two hallmarks and two enabling characteristics. Adopted from Hanahan et 
al2. 
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1.2.1 Self-sufficiency in growth signal.  
 
For normal active proliferation, healthy cells will generally require the passage and 
conduction of stimulating signals. For this to happen, specific extracellular signalling 
molecules are required, in addition to membrane bound or transmembrane 
receptors3 (Figure 1.2), including adhesion molecules such as integrins and 
cadherins4. Such signalling molecules could be components of the extracellular 
matrix such as collagen and glycoproteins5, or soluble growth factors such as bFGF 
and VEGF6.  
 
Figure 1.2 Signal passage and conduction: 
Illustration of the concept of signal passage and conduction to generate response 
such as proliferation. It involves the binding of a ligand to membrane bound or 
transmembrane receptors, leading to conformational changes and the generation of 
response. Adopted from Lappano et al7.  
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These bind as ligands to specific membrane bound receptors for onward transmission 
of signals intracellularly. An example is illustrated in (Figure 1.3), in which the RAS-
RAF-MEK1/2 pathway is activated by the binding of ligands which could be soluble 
growth factors, hormones or other stimuli, with resultant transmission of signals 
intracellularly, culminating in one form of response or the other such as proliferation 
or influence on gene expression8.  
 
 
Figure 1.3 MAPK pathway: 
An illustration of the MAPK pathway. Adopted from Martineli et al, 20178. 
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It is therefore apparent that normal cells rely on external or exogenous molecules for 
the maintenance of growth or proliferation. This reliance on exogenous factors is less 
apparent with tumour cells which are often able to mimic signal transduction in a 
number of ways and trigger as well as sustain cell proliferation. An example is the 
case where a HIF-1α dependent autocrine feedback was shown to enhance survival 
of prostate cancer cells starved of serum9. This acquired growth signal autonomy is 
thought to be modulated by numerous oncogenes which act in favour of tumour 
proliferation. Equally, the normal tightly regulated growth signal pathway may be 
deregulated at any of the three distinct phases – the extracellular molecules, the 
transmembrane receptors, or the intracellular mechanism responsible for translation 
of signals into action, such as the SOS-Ras-Raf-MAP cascade10 (Figure 1.3). With 
autocrine stimulation, tumour cells are able to manufacture and respond to growth 
molecules without dependence on other neighbouring cells for supply. An example 
is the autocrine stimulation of glioblastomas by PDGF (platelet-derived growth 
factor)11. Deregulation of membrane bound receptors often exists in the form of 
overexpression of such receptors, thereby making the tumour cells hypersensitive to 
normal or subnormal levels of growth factors. A notable example is the case of 
increased expression of EGFR in brain and breast cancer12,13. The overexpressed 
receptors may even signal constitutively without the binding of ligands, further 
stimulating the proliferation of tumour cells14,15. In a more complex manner, still very 
much less understood, deregulation can occur within the intracellular mechanism 
responsible for the translocation of signals into action. A notable example is the Ras 
protein in the SOS-Ras-Raf-MAP cascade, in which the Ras protein is found to be 
structurally altered in about 25% of cancer cases16. This structural alteration leads to 
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constitutive signalling, even in the absence of stimulations by ligand-receptor 
complexing16. 
 
 
1.2.2 Insensitivity to antigrowth signals.  
 
Similar to the need for growth signals for proliferation, antigrowth signals also exist. 
These signals work in a coordinated manner for the homeostasis of cells, ensuring a 
balance in the rate of growth / proliferation. Antigrowth signalling molecules may be 
in the form of soluble molecules, immobilised components of the ECM, or indeed as 
cell membrane receptors17. Cells do not generally replicate endlessly. They are 
induced into a temporary G₀ phase from an active proliferative phase, or into a more 
permanent postmitotic/differentiation state18. This is mainly via the retinoblastoma 
protein family19, and tumour cells have to devise a means of evading this control in 
order to sustain proliferation. Normally, among other antigrowth factors, TGFβ 
prevents the phosphorylation of pRb, thereby keeping it in the hypophosphorylated 
state. In this state, pRb hinders the ability of E2F to promote expression of an array 
of genes responsible for the progression of cells from the G1 phase into the S phase. 
Upstream deregulation with TGFβ or its receptors truncates this system, resulting in 
hyperphosphorylation of the pRb and therefore enhanced E2F function, ultimately 
leading into cells moving from the G1 phase to the S phase20 (Figure 1.4).  
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Figure 1.4 The pRB-E2F pathway: 
The pRB-E2F pathway is illustrated with E2F shown to be inhibited by the binding of 
pRB. This occurs in the G₀ and G₁ phase. In proliferating cells however, the Cyc D / 
Cdk4/4 complex enables the phosphorylation of pRB to release E2F. The released E2F 
induces genes for S phase. The pRB-E2F complex is disenabled by mutations in the RB 
gene in cancer.  
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1.2.3 Evading apoptosis.  
 
The regulated and orchestrated cellular process in both physiological and 
pathological settings, leading to cell death and phagocytosis of the dead cells is 
referred to as apoptosis21-23. Two groups of key players in the apoptosis pathway 
include sensors and effectors. The former monitors both intracellular and 
extracellular environment for abnormalities such as DNA damage / hypoxia and cell 
attachments, leading to a trigger of programmed cell death that is carried out by 
“effectors”24. There is also directed cell killing via death ligands, for instance, cells 
expressing Fas or TNF receptors trigger or initiate the process of apoptosis by binding 
to death ligands and protein cross-linking25,26.  
It is important to note also that cells generally maintain their existence based on vital 
“cell-matrix” and “cell-cell” interactions which generate signals necessary for normal 
cell function. This inherent cell-cell / cell-matrix mechanism for supply of signal will 
have to be compromised for cell death to occur under normal circumstances27,28. The 
mitochondrion is the power house of the cell. It is therefore no surprise that most of 
the apoptotic signals are targeted at this organelle which, in response, releases the 
cytochrome C protein to herald cell destruction29. This release is governed by the Bcl-
2 family, which are either pro- or anti-apoptotic through their stimulation or 
inhibition of this release of Cytochrome C, respectively30 (Figure 1.5). The effectors 
of apoptosis are the caspases, which eventually bring about controlled cell death 
(Figure 1.6). They begin this by initiating the execution pathway, triggered by 
cleavage of caspase-3. The pathway involves the fragmentation of DNA and other 
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cellular events such as degradation of cytoskeletal and nuclear proteins, and cross 
linking of proteins.  
 
 
Figure 1.5 Members of the Bcl-2 family: 
Members of the Bcl-2 family of proteins grouped into pro- and anti-apoptotic sub-
groups. Adopted from L. Scorrano et al.30 
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There is formation of apoptotic bodies and late in the execution pathway, uptake of 
the apoptotic cells by phagocytic cells following expression of ligands for phagocytic 
cell receptors25. For cancer cells to thrive therefore, they must devise a means of 
deactivating the apoptotic pathway/machinery. Tumour cells are able to achieve this 
through a variety of ways, the most common is via p53 mutation, observed in more 
than 50% of cancer cases31. This is no surprise, considering the transcriptional 
activities of p53 generally lead to the activation / upregulation of downstream target 
genes such as MDM2 and CDKN1A. These in turn are involved with cellular activities 
that bring about cell cycle arrest, DNA repair, senescence and programmed cell 
death. Inactivating mutations in p53 will therefore promote increased proliferation 
and possibly metastasis31. Indeed, tumour cells have been shown to use many 
different mechanisms to abrogate the apoptotic pathway, including transcriptional / 
translational and post translational regulation of proteins. Transcriptional / 
translational approach involves overexpression of anti-apoptotic proteins and the 
suppression of pro-apoptotic proteins expression, while the pro-translational 
regulation involves steps such as altering protein function, destruction of pro-
apoptotic proteins and stabilizing MCL-132. For instance, it has been demonstrated in 
lung and colon cancer cell lines that the existence of a false FAS receptor competes 
with active FAS receptors for the pro-apoptotic FAS ligand, thereby limiting 
apoptosis33. 
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Figure 1.6 intrinsic and extrinsic pathways of apoptosis: 
An illustration of both intrinsic and extrinsic pathways of apoptosis22. 
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1.2.4 Limitless replicative potential.  
 
It is proposed that there is an inherent mechanism by which normal cells restrict the 
number of cell divisions they can undertake. For example, cells placed in culture will 
normally not continue to replicate indefinitely, rather they will achieve a finite 
number of replications and then reach a state of senescence after a number of 
duplications34. Replication may be pushed further to a stage known as the “crisis 
point”, characterised by massive cell death35. It is estimated that 1 in 10⁷ of such cell 
population escape entirely to become immortalised, replicating indefinitely36. 
Tumour masses are thought to comprise of a variety of cell types, including a 
population of immortalised cells37,38. Finite replication found normally with cells may 
be attributed to progressive loss in telomere with every cycle of cell duplication. With 
this loss, chromosomes are left unprotected and thus exposed as targets for DNA 
damage39,40, and telomere maintenance is observed in malignant cells. This is majorly 
due to upregulation of the telomerase enzyme. This in turn ensures that the telomere 
DNA repeats (TTAGGG), are constantly replenished and maintained at the 3´ ends of 
the chromosomes, following rounds of cell replication41. That way, telomere 
shortening is prevented, cellular replication is maintained and DNA damage 
prevented. 
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1.2.5 Sustained angiogenesis. 
 
To thrive, cancer tissues develop angiogenic potentials to ensure effective nutrient 
and oxygen supply42,43. Signals for this are generated by soluble factors and their 
corresponding endothelial membrane bound receptors, typified by VEGF (vascular 
endothelial growth factor), which binds to its endothelial membrane bound tyrosine 
kinase receptors, neuropilin-1/244. Signalling by VEGF (vascular endothelial growth 
factor) is generally required for both vasculogenesis (formation of new blood vessels 
from angioblasts during embryogenesis), and angiogenesis (formation of new blood 
vessels from already existing vasculature)45,46. There exist an almost equal number of 
endogenous inhibitors to angiogenesis as there are stimulators, this therefore 
suggests the process of vasculogenesis is tightly as well as critically regulated with the 
balance between both groups of stimulator and inhibitors. Interference with those in 
support of angiogenesis will therefore inhibit angiogenesis 47. Thrombospondin-1 is a 
typical example of a potent angiogenic inhibitors48. This member of the 
thrombospondin family of proteins, synthesised, secreted and functioning in the 
extracellular matrix, regulates angiogenesis by direct and indirect means49. Direct via 
physical impact on vascular endothelial cells, and indirectly via other angiogenic 
regulators49. Taken together, several investigations point to the fact that 
angiogenesis or formation of new capillaries is likely to be a prerequisite for the 
growth of tumours50, and that tumours are able to switch from a quiescent state of 
capillary formation to active angiogenesis51.  
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1.2.6 Tissue invasion and metastasis.  
 
Invasion and metastasis are both forms of tumour dissemination, and are considered 
the most deadly acquired capabilities of tumours, as they render the tumours more 
difficult to manage following spread to other tissues52. Tumour metastasis in 
particular is put as the leading cause of mortality due to cancer53. It is the general 
believe that after tumours have exhausted their initial and primary site, they will tend 
to spread to neighbouring or distant sites to create additional space. There is 
however the view that, prior to when crowding becomes an issue, and at the initial 
stage of tumour establishment and growth, invasion and metastasis or dissemination 
of tumour cells may still occur52,54. Tumour cells invade neighbouring sites but 
metastasise to farther niches, tumour metastasis is therefore the establishment of 
secondary tumours at a location entirely different from their primary site55. Table 1.1 
highlights the notable differences between invasion and metastasis56. They 
metastasise by first invading the surrounding stroma, then travel through blood or 
lymphatic vessels before migrating out to form new colonies57 (Figure 1.7).  
Table 1.1 Metastasis and invasion 
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Figure 1.7  Illustration of tumour invasion: 
Illustration of tumour invasion, gradually into neighbouring stroma and on to blood 
vessels for possible distant seeding. 
 
This process of seeding and the conditions of an entirely new environment will 
generally appear harsh on the seeded cells, but, due to genetic instability and 
heterogeneity of tumour cells, they are said to be able to generate a subset of cells 
with a phenotypic characteristic that enables them withstand such otherwise 
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incompatible and new microenvironment58. The acceptability or accommodating 
nature of the new microenvironment, mostly determined by the nature of its stroma 
organisation is a huge factor for successful seeding57.  
Expressions of CAM (cell adhesion molecules) members of the immunoglobulin 
family and cadherins, and integrins by tumour cells has been shown to be an 
important feature in the survival of metastatic tumours in their new site59. 
 
1.2.7 Reprogramming energy metabolism 
 
Neoplasm generally entails increased tissue growth and proliferation, thereby 
increasing the demand on energy metabolism. Under normal physiological 
conditions, healthy cells are known to, under aerobic conditions, process glucose by 
converting same into pyruvate. This occurs during glycolysis and takes place largely 
in the cytosol of cells60. The resultant pyruvate is channelled into the mitochondria 
for onward production of CO₂, with a positive gradient in Oxygen concentration 
favouring this mitochondria reaction61. It is therefore the normal trend to have more 
pyruvate channelled into the mitochondria for conversion into CO₂, a process known 
as oxidative phosphorylation, in aerobic conditions. Tumour cells have been shown 
to possess the ability to act in the contrary, rather favouring reaction in the opposite 
direction - a condition first described by Warburg and known as aerobic glycolysis62,63. 
Oxidative phosphorylation will usually produce abundant ATP, therefore, a metabolic 
switch in favour of glycolysis will incur shortage in ATP, put at approximately 18 fold 
less. To compensate for this reduced efficiency in ATP production, cancer cells 
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increase uptake of glucose to compensate via increased glycolysis. They achieve this 
by the upregulation of glucose transporters such as GLUT164. This increased glycolysis 
adopted by tumour cells has also been demonstrated to be associated with tumour 
suppressor genes such as p53 as well as oncogenes such as MYC and RAS65. With this 
capability, cancer cells are able to cope in an ensuring hypoxic condition mostly due 
to excessive demand for oxygen and possible cell / tissue overcrowding. In which case 
they are able to upregulate enzymes favouring glycolysis such as HIF1α and HIF2α, as 
well as glucose transporters66. It is thought that the increased glycolysis provides 
essential substrates for the supply of amino acids, necessary for the assembly of new 
cells and their organelles67. The limitations of this emerging hallmark are as follows. 
Firstly, it has been shown that some tumours consist of two subpopulations, with 
different substrate requirements in respect to energy metabolism. One 
subpopulation requires glucose with lactate waste, with the other subpopulation 
requiring the same lactate waste for its metabolism, thus making them co-exist 
symbiotically68. Taken together therefore, it means this emerging hallmark may not 
exactly be applicable to all tumour cells and that the metabolic twist may simply be 
one of the routine adaptation features for cells in general, and maybe more with 
tumour cells. 
 
1.2.8 Evading immune destruction      
 
Protection offered by the immune network should also entail surveillance for 
tumours and thus preventing them from becoming established. For tumour cells to 
become established therefore, they will have to devise a means by which they are 
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able to evade this immune surveillance or destruction. The fact that the incidence of 
certain cancer types increases in immunocompromised states69, may add credence 
to the above proposition. An experiment to further illustrate the importance of the 
immune system against tumour formation, using immunodeficient mice showed that 
a deficiency in either T cells or natural killer cells (NK) increased susceptibility to 
tumour formation70. In support of this, transplantation experiments showed that, 
weakly immunogenic cancer cells originating from immunocompromised primary 
hosts fail to thrive or seed when implanted unto immunocompetent secondary hosts, 
unlike when they are transplanted unto correspondingly weak secondary hosts71. 
From the clinical epidemiology point of view, colon and ovarian tumours are said to 
be less aggressive after massive infiltration with both cytotoxic T lymphocytes (CTLs) 
and NK cells, unlike those that lacked the immune cells72. Similarly, patients who 
receive organ transplants may develop donor-derived tumours due to their state of 
immune-suppression, whereas their donors have had the cancer cells dormant, 
possibly as a results of their enhanced immunity73. An obvious loophole in this 
emerging hallmark is the fact that there is currently no data suggesting that 
immunocompromised individuals are on an overwhelming majority in terms of 
cancer sufferers. 
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Figure 1.8  circuits and sub-circuits in cancer cells: 
A simplified schematics of circuits and sub-circuits operating in cancer cells to 
regulate the hallmarks discussed2.   
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1.3 Enabling characteristics of cancer 
 
1.3.1 Genome instability.  
 
It is generally accepted that for cells to become cancerous, on the basis of genetic 
changes, mutations accumulate to trigger or sustain carcinogenesis74. Healthy cells 
under normal physiological conditions are therefore unlikely to become cancerous, 
having inherent checks against cell cycle aberrations in addition to mechanisms in 
place for repair of damaged DNA75. The fact that cancer occurrence is generally more 
frequent than expected does suggest that cancer cells may be more susceptible to 
mutations, for them to be able to acquire a sufficient number of mutations put 
together to trigger carcinogenesis76. In colorectal cancer for instance, DNA repair is 
commonly aberrant, leading to an accumulation of muatations77. This susceptibility 
may be in the form of depreciation in the mechanisms acting as checks against cell 
cycle abnormalities, and those responsible for repair of damaged DNA. This is 
exemplified with loss in function of the p53 DNA damage repair pathway, noticed in 
several cancer types78,79.   
 
1.3.2 Tumour-promoting inflammation                     
 
Almost every tumour is infiltrated to some degree by immune / inflammatory cells72. 
It is thought that the infiltrating immune cells, particularly those of the innate 
immune system are helpers for tumour progression rather than the logical opposing 
role they are expected to play80. It is proposed that the mechanism by which they 
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achieve this has to do with the inflammatory cells enabling increased bioavailability 
of important molecules such as growth factors for increased proliferation, survival 
factors, proangiogenic factors and possibly ECM anchorage factors. All of these 
working together would enhance tumour invasion and metastasis80,81. In addition, 
the inflammatory cells are likely to enhance production of reactive oxygen species 
which enable neighbouring settling cancer cells acquire full status and thus promote 
malignancy82. 
 
1.4 The oral cavity:  
 
The oral cavity is one of the major openings into the human body. It is important for 
digestion, speech, taste and respiration. Component parts are; the upper and lower 
lips with their labial mucosa and commissures, the upper and lower vestibules, the 
gingiva, the buccal mucosa, the mandible and maxilla including the dentition, the 
floor of the mouth, the anterior two-third of the tongue, also known as the oral 
tongue, the hard palate, and the retromolar region. The oral cavity opens posteriorly 
into the oropharynx which traditionally comprises the soft palate, tonsils and the 
posterior one-third of the tongue (Figure. 1.9). Some component parts are concealed 
to an extent, as a result, diseases or tumours may easily go unnoticed at their early 
stages. Patients with squamous cell carcinoma of the retromolar region for instance 
often present late83, and nasopharyngeal cancers are not easily detected because of 
their anatomical location84. A good understanding of the gross anatomy of the region 
is therefore important.   
 45 
 
 
 
Figure 1.9  lateral cross section of the head and neck: 
A lateral cross section of the head and neck region showing the position of the oral 
cavity in relation to other parts of the head and neck. The image is obtained from the 
Canadian cancer society  
 
1.4.1 The lip 
 
The oral cavity is bounded anteriorly by the lips, laterally by the cheeks, inferiorly by 
the floor of the mouth, superiorly by the hard palate and posteriorly continues into 
the oropharynx (Figure 1.9 & 1.10). The upper and lower lips form the surrounding 
to the opening of the oral cavity and play important roles in competence of the mouth 
and facial expression, while also aiding mastication and phonation. The upper lip 
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extends from the base of the nose superiorly and runs laterally towards the nasolabial 
folds, ending inferiorly at the vermilion border. The lower lip extends from the 
mandible inferiorly and runs laterally to meet the upper lip at the commissures. 
Histologically, from superficial to deep, the upper and lower lips comprise the 
epidermis, subcutaneous tissue, orbicularis oris, and the mucosa. The vermilion with 
its characteristic colour is composed of nonkeratinised squamous epithelium. Apart 
from the vermilion part of the lips, there are numerous minor salivary glands, 
sebaceous glands and hair follicles85-87. 
 
 
 
 
Figure 1.10  anterior view of the oral cavity: 
An anterior view of the oral cavity showing its main component parts. Image obtained 
from the Canadian cancer society87.  
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1.4.2 The tongue 
 
The anterior two-thirds of the thick muscular tongue is part of the oral cavity and it 
is almost entirely covered by mucous membrane, with a characteristic appearance 
due to covering by lingual papillae88. 
 
 
1.4.3 The floor of the mouth 
 
The main excretory duct of the submandibular gland, also known as Wharton`s duct, 
is found in the floor of the mouth with other smaller duct openings from the 
sublingual gland. The floor of the mouth is the inferior limit of the oral cavity.  
 
 
1.4.4 The hard palate 
 
This comprises of the anterior two-thirds of the palate, and it is much bonier 
compared to the soft posterior one-third of the palate. It basically separates the oral 
cavity from the nasal cavity89. It is bounded antero-laterally by the maxillary teeth, 
and superiorly by the respiratory epithelium of the nose. Its inferior border is the 
masticatory epithelium of the oral cavity, while continuing posteriorly with the soft 
palate. Feeding and phonation are the main functions of the hard palate, with both 
functions hampered in deformities such as cleft palates89.  
 48 
 
1.5 Oral cancer 
 
Oral squamous cell carcinomas (OSCC) arise from stratified squamous epithelium of 
the oral mucosa90. OSCC incidence increases with age, common with people above 
the age of 40 years, with the most frequently affected sites being lateral tongue, lip 
and floor of the mouth 91-93. Head and neck cancer was reported to be the eighth 
most common cancer type in the UK in 2014. Worldwide, it is the sixth leading cancer 
type by incidence with more than 550,000 cases and about 300,000 deaths in 201493. 
Oral squamous cell carcinomas (OSCC) are the commonest forms of head and neck 
cancer94. Incidence of oral cancer varies from region to region due to marked 
differences in nutritional as well as socio-cultural habits95. Risk factors for all Head 
and neck cancer anatomical sites include; tobacco, alcohol, betel quid, family history, 
ionising radiation, and age. Other, more site-specific risk factors include infections 
such as human papillomavirus (HPV) in oropharyngeal cancer96, Epstein-Barr virus 
(EBV) in nasopharyngeal cancer97 and Burkitt`s lymphoma98, as well as Human 
immunodeficiency virus (HIV) and Acquired immune deficiency syndrome (AIDS) in 
Kaposi`s sarcoma99. Immune system deficiencies resulting from conditions such as 
organ transplant and autoimmune conditions are also risk factors100, as are 
occupational hazards such as exposure to acid mists, asbestos, formaldehyde, wood 
dust and rubber production93. Rare inherited disorders such as Fanconi anaemia101, 
Li Fraumeni102 and Tylosis103 have also been implicated as risk factor for head and 
neck cancers. Oral cancers are often diagnosed rather late with two-third already 
significantly locally advanced before they are diagnosed104. Symptoms of oral cancer 
include: swelling or thickening of the affected part, non-healing ulcers, leukoplakia 
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(white patch), erythroplakia (red patch), pain on chewing, swallowing or speaking, 
bleeding, numbness, halitosis, mobile teeth, weight loss and neck lumps105. As a 
consequence of genetic and epigenetic alterations which form the basis for which 
carcinogenesis occurs, constituent cells for each cancer type do not only appear 
morphologically similar, but also tend to show upregulation/downregulation of 
specific proteins considered biomarkers. For OSCC, deregulation is commonly 
reported with genes such as p53, retinoblastoma gene, VEGFR, EGFR and recently 
notch92,106.  Treatment modalities are by surgical excision, chemotherapy or 
radiotherapy, or a combination of any two or the three107,108.  
Classification or grading of oral cancer is important for the determination of 
prognosis and for effective treatment planning109,110. The TNM classification for 
instance, which is based primarily on anatomical location, is important for overall 
effective clinical care, also to aid in determining cases for clinical trials, for 
stratification, clinical and molecular research, as well as policy making110. Staging has 
been shown to be of importance, with cases treated differently according stage, with 
success111. Among other criteria, oral cancer may be classified according to primary 
site – cancer of the lip, tongue, floor of the mouth, palate, mandible, retromolar 
region, maxilla and vestibule. Also according to the pattern of the tumour invasion 
front or based on the level of differentiation of tumour cells92,112. Staging oral cancer 
puts clinical and pathological features into consideration and overall, the tumour 
stage gives an idea of extent of tumour and its prognosis113. The TNM form of staging 
considers tumour size (T), involvement of regional lymph nodes (N), and metastasis 
(M)114. Table 1.2 shows details of the TNM staging system.  
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1.5.1 Genetic predisposition to head and neck squamous cell carcinomas.  
 
It is already common knowledge that certain factors such as alcohol, tobacco and 
viral infections such as HPV are risk factors for the formation of head and neck 
cancers. In addition, individuals may be additionally predisposed or with an increased 
risk of developing HNSCC, genetically. Patients with the autosomal recessive Fanconi 
anaemia syndrome and families with mutations in CDKN2A and ATR genes have been 
shown to have an elevated tendency of developing head and neck cancer115-118 . This 
is in addition to predictions that abnormalities in DNA damage repair pathway for 
instance may further add to susceptibility to risk factors such as alcohol and tobacco 
causing HNSCC119. 
 
 
1.6 Other forms of head and neck cancer 
 
Apart from oral cancer, other common cancer sites in the head and neck region 
include: oropharyngeal cancer, nasopharyngeal cancer, laryngeal cancer and 
hypopharyngeal cancer.  
 
1.6.1 Oropharyngeal cancers  
 
Oropharyngeal cancers affect the oropharynx which is the part of the throat directly 
posterior to the mouth (Figure 1.11). Functional parts of the oropharynx include the 
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soft palate, base of the tongue, part of the throat occupied by the tonsils, and the 
posterior pharyngeal wall. The commonest histological form is oropharyngeal 
squamous cell carcinoma. Other forms include sarcomas, lymphomas, melanomas, 
and a few affecting regional salivary glands120. Common risk factor of oropharyngeal 
cancer include alcohol, smoking, chewing tobacco, HPV infection and poor diet. 
Symptoms include unexplained weight loss, appearance of a painless neck swelling, 
sore throat/tongue, ear pain, altered voice and halitosis. Treatment in the UK is 
through one or a combination of surgery, radiotherapy and chemotherapy121,122.  
 
 
Figure 1.11 Lateral view of the head and neck: 
Lateral view of the head and neck region highlighting the oropharyngeal space123. 
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1.6.2 Nasopharyngeal cancers 
 
Nasopharyngeal cancers affect the nasopharynx, which is part of the throat just 
posterior to the nasal region (Figure 1.11). The squamous cell carcinoma form is one 
of the histological variant, with others such as non-keratinising carcinomas and 
basaloid squamous cell carcinomas. In areas where nasopharyngeal cancers are 
prevalent, such as Southeast Asia and Southern China, the non-keratinising 
carcinoma variant is commonest with an incidence of as high as 90%124. Its main risk 
factor apart from the general risk factors for head and neck cancers is EBV (Epstein-
Barr virus) infection98, reported to be clonally present in almost a hundred percent of 
all undifferentiated nasopharyngeal cancer cases125. Notable symptoms include 
painless upper neck swelling, ear pain with possible leakage of fluid from the ear, 
blocked nose with bleeding, headache and hearing difficulties126. The main treatment 
modality is radiotherapy, but there may be a combination with chemotherapy127. 
 
 
1.6.3 Laryngeal cancers 
 
Laryngeal cancers affect areas around the vocal cords (glottis). The larynx is 
essentially the voice box with the sub-regions, the superior supraglottis, the glottis, 
and the inferior subglottis (Figure 1.12). Cancer variants in this region include 
squamous cell carcinomas, sarcomas, lymphomas, adenocarcinomas and 
neuroendocrine carcinomas128. Symptoms of laryngeal cancer include classical 
hoarseness of the voice and neck swellings which may be painful129,130. Treatment 
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modalities include surgery, radiotherapy, chemotherapy and recently gene 
therapy131,132.  
 
 
 
 
Figure 1.12  Lateral view of the head and neck: 
Lateral view of the head and neck region showing the larynx129 
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1.7 Genetics of oral cancer.  
 
Formation and progression of oral cancers, like other cancer types have been 
attributed to genetic alterations or abnormalities. Chromosomal instability resulting 
in altered number of chromosomes, often arising from defects in chromosome 
segregation is common with cancer cells133. Significant chromosomal instability is 
observed in 80% of HPV-negative HNSCC cases, and these include changes with the 
chromosomal arm-level as well as smaller focal alterations134. Using fluorescence in 
situ hybridisation (FISH) to analyse fine needle aspiration biopsy (FNAB) specimens, 
instability in chromosomes 7, 9 and 11 alone was demonstrated in 11.7% of OSCC 
patients135. Apart from aberrations in cell cycle, common in cancer, aneuploidy, 
which is the gain or loss of one or more chromosomes thereby altering the total 
number of DNA assembly of a cell, is also a commonly observed characteristic136,137. 
In a TMA study involving 47 non-metastasised and 39 metastasised primary OSCC 
cases, aneuploidy was demonstrated in all the cases as well as all affected lymph 
nodes138. Also, in a multi-centre analysis of tongue squamous cell carcinoma in 37 
patients to determine correlation between DNA ploidy and clinicopathological 
characteristics, aneuploidy was detected in 86.5% of the cases139.   
Oncogenes and tumour suppressor genes are also affected by DNA copy number 
alterations, often due to deletions and duplications, with the tumour suppressor 
gene, CDKN2A/2B and the MTAP metabolic enzyme found to be co-deleted in 6/16 
cancer cases in a study140. Primary OSCC cells were shown to have acquired a 
metastatic form by gaining metastasis- associated copy number alteration. In a study 
on copy number aberrations, using metastatic primary tumours and their paired 
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affected lymph nodes, gains and losses were most commonly observed in (3q, 9q, 
11q13, 14q, 16p, 18p, and 20q) and (3p, 4q, 8p, 9p, 10p, 13q, 18q, and 21q) 
respectively in more than 50% of cases141. Loss of heterogeneity is another genetic 
occurrence that may lead to affected cells becoming cancerous142,143, and this has 
been shown in oral cancer cases, with the loss of heterogeneity mostly affecting 
tumour suppressor genes and oncogenes. This was highlighted in a study 
demonstrating large-region-LOH in 3p, 17p and especially 9p chromosomes, with 9p 
housing genes such as KDM4C, CCDC171, IL33 and FREM1, all thought to be tumour 
suppressor genes for HNSCC144. Loss of heterogeneity in p53 gene was notably 
demonstrated in oral cancer cases, and the p53 gene is well established as a major 
tumour suppressor gene145. With the use of microarray technology and next 
generation sequencing, researchers have recently been able to carry out a 
comprehensive genomic profiling of head and neck cancers and their commonly 
mutated tumour suppressor and oncogenes (unravelling the molecular genetics of 
head and neck cancer through genome-wide approaches). 
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Table 1.2: TNM staging system for oral cancer (obtained from the International 
agency for research on cancer, IARC)146 
T – Primary tumour size 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension 
T2 
Tumour more than 2 cm but not more than 4 cm in greatest 
dimension 
T3 Tumour more than 4 cm in greatest dimension 
T4a (lip) 
Tumour invades through cortical bone, inferior alveolar nerve, 
floor of mouth, or skin (chin or nose) 
T4a (oral 
cavity) 
Tumour invades through cortical bone, into deep/extrinsic muscle 
of tongue (genioglossus, hyoglossus, palatoglossus, and 
styloglossus), maxillary sinus, or skin of face 
T4b (lip 
and oral 
cavity) 
Tumour invades masticator space, pterygoid plates, or skull base; 
or encases internal carotid artery 
 
N – Involvement of regional (cervical lymph nodes) 
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NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 
Metastasis in a single ipsilateral lymph node, 3 cm or less in 
greatest dimension 
N2  Metastasis as specified in N2a, 2b, 2c below 
N2a  
Metastasis in a single ipsilateral lymph node, more than 3 cm but 
not more than 6 cm in greatest dimension 
N2b 
Metastasis in multiple ipsilateral lymph nodes, none more than 6 
cm in greatest dimension 
N2c  
Metastasis in bilateral or contralateral lymph nodes, none more 
than 6 cm in greatest dimension 
N3  Metastasis in a lymph node more than 6 cm in greatest dimension 
 
M - Distant metastasis 
 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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Overall stage grouping 
 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1, T2 N1 M0 
 
T3 N0, N1 M0 
Stage IVA T1, T2, T3 N2 M0 
 
T4a N0, N1, N2 M0 
Stage IVB Any T N3 M0 
 
T4b Any N M0 
Stage IVC Any T Any N M1 
 
 
1.8 Gene mutations and alterations in HNSCC.  
 
It is a common trend for literature to site data from HNSCC as a whole, rather than 
specifically OSCC, and I will be following the trend. Gene mutations have been shown 
to be common in sporadically occurring (apart from the familial cases) cancers. A 
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study of 30 different tumour types ranked HNSCC as the 9th highest in terms of gene 
mutation load (ranging from 1-100 mutations per Mb)147 . Table 1.3 shows a summary 
of commonly mutated genes arising from three studies of head and neck cancer and 
the Indian LGC134,148. A cohort of the commonly mutated genes are hereby discussed. 
 
 
Table 1.3 Tumour suppressor genes and oncogenes commonly associated with 
HNSCC134. 
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1.8.1 p53 
 
The transcription factor and tumour suppressor gene, p53, is known to be frequently 
mutated (46-73%) in HNSCC148. It contains the highly conserved DNA binding domain 
(DBD) and is activated in response to cellular abnormalities such as oxidative stress 
and DNA damage. This leads to cell cycle arrest to allow repair, failure of which leads 
to either apoptosis or senescence. Both missense and nonsense mutations are 
characteristics of the p53 mutational spectrums, with nonsense mutations being 
randomly distributed, but missense mutations directed at the DBD149. The fact that 
p53 mutations are also present in pre-malignant lesions strengthens the theory that 
p53 mutation is important in the early stages of cancer formation 106,150-152. p53 may 
also be inactivated via upregulation of its negative regulator, MDM2153,154. In terms 
of significance of p53 mutation, a study using a cohort of about 420 HNSCC patients 
showed that mutations in p53 correlated with poor survival, and further worsened if 
mutations are in the DBD 155.  
 
1.8.2 CDKN2A, CCND1 and RB1 
 
The important cell cycle progression moderator, Retinoblastoma protein (RB1) is 
regulated by the upstream CDKN2A/CCND1 pathway156. For this reason therefore, 
the three proteins are mentioned together. In about 30% and 20% of HNSCC cases, 
CDKN2A gene is deleted and mutated respectively134,157. The cell cycle genes-
CDKN2A, CCND1 and RB1 are frequently altered in HNSCC. Mutations in the CDKN2A 
gene, including splice site changes, nonsense mutations and frame shifts, generally 
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lead to inactivation of the gene, and this effect is increased where there are 
additional epigenetic alterations158 . Cyclin D1 is a cofactor, together with CDK4 and 
CDK6 for the phosphorylation of Rb and its gene159,160. CCND1 is reported to be 
altered in form of amplification in over 20% of tumours, with low levels of mutations 
and epigenetic alterations also reported. In about 5% of patients, the retinoblastoma 
gene, Rb1 is shown to be either mutated or deleted 161. Put together, it has been 
shown that differential deregulation of the genes of the CDKN2A/CCND1-CDK4-RB1 
pathway is associated with the pathogenesis of HNSCC162. The biggest impact came 
from the deregulation of CDKN2A, especially in the early stages of disease, with 
deregulation of the other component genes thought to add to the effect and 
prominent at the later stages of disease162.  
 
 
1.8.3 PIK3CA and Epidermal growth factor receptor 
 
PIK3CA is hereby discussed with Epidermal growth factor receptor (EGFR), having 
been shown that mutations in both genes frequently coexist163. PIK3CA is another 
commonly mutated gene in malignancies generally, including HNSCC, whose 
deregulation is thought to play significant roles in tumour growth and metabolism 164-
166. EGFR is able to indirectly activate PI3K after dimerization with members of the 
erbB family. This activation leads to further activation of AKT via phosphorylation of 
phosphatidylinositols. AKT either acts as a direct downstream effector of the PI3K 
pathway or indirectly by activating mTOR which is important for the regulation of 
cellular nutrient levels and energy stores134 . Overall, PIK3CA mutation has been 
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reported in as many as 20% of HNSCC cases167, particularly in HPV-positive 
tumours168,169.  
Activation of the epidermal growth factor receptor (EGFR) upon binding to its ligand 
leads to dimerization with other members of the tyrosine kinase erbB group of 
membrane receptors to which it belongs. This eventually leads to conformational 
changes and subsequent activation of downstream target genes/pathways such as 
RAS/RAF/MAPK which are important regulators of cellular features such as 
proliferation, metastasis, invasion and angiogenesis 170. EGFR is expressed in majority 
of HNSCC tumours and a correlation has been shown between level of expression and 
prognosis171. Therapeutic interventions targeting EGFR have however not been as 
successful as expected. This may be due to a lack of understanding of the precise 
mechanisms by which EGFR plays its pathogenic role, or basically as a result of the 
presence and effect of some other non-EGFR alternative pathways172-176.  
 
 
1.9 Notch pathway 
 
1.9.1 Overview of Notch signalling pathway 
 
The notch pathway is one of the major pathways acting both individually and co-ordinately 
to interpret and transmit extrinsic signals, presenting such as distinct transcriptional 
responses177. The Notch signalling family consists of a group of transmembrane 
proteins coded for by the notch family of genes: Notch 1, 2, 3 and 4178,179. 
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Discovered about a century ago in Drosophila through notches in their wing margins, 
these proteins are generally composed of a large extracellular and a smaller 
intracellular domain (Figure 1.13). Five notch ligands: delta-like1, delta-like3, delta-
4, Jagged-1&2180-182, have been identified in mammalian systems183, and they are 
equally membrane bound like their receptors184 (Figure 1.14). The activation of the 
Notch receptor is controlled by regulated intramembrane proteolysis (RIP) in which, 
the binding of a Notch ligand is believed to initiate a proteolytic cascade resulting in 
the release of the Notch intracellular domain (NICD) and subsequent activation of 
immediate downstream target  genes such as Hes-1, Hes-5, Mash-1 and Neuro-
D185,186 (Figure 1.13 & 1.14). Recent studies reveal that apart from the well-
established fact that the Notch pathway takes part in differentiation of cells / 
tissues184,187-190, it is now widely believed that both proliferation and apoptotic events 
can be modulated by Notch signalling191.  
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Figure 1.13  Notch signalling pathway illustrated192. 
 
 
1.9.2 Role of Notch signalling in HNSCC 
 
The exact role of the Notch signalling pathway in the pathogenesis of head and neck 
cancers has been on the spotlight of recent investigations, with defects in this notch 
signalling pathway linked with the pathogenesis of HNSCC193,194. Mutations in Notch 
genes and receptors195-197, altered RNA / protein expression197-199, and constitutive 
activation of Notch without need for ligand binding, have all been reported in 
HNSCC200. With regards to Notch mutations, Notch1 mutation has been reported in 
as much as 10% to 15% of HNSCC cases, making it only the second most mutated 
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gene in HNSCC, with p53 the most commonly mutated197. In their comprehensive 
study which involved the use of a cohort of 44 HNSCC and 25 normal samples, a 
bimodal pattern of Notch pathway alteration was observed with a more obvious 
inclination towards activating mutations rather than inactivating mutations197.  
 
 
 
Figure 1.14 Notch signalling by RIP: 
Schematic to illustrate notch signalling being mediated by regulated proteolysis. 
Image adopted from Raphael Kopan201 
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A smaller cohort of 11% of tumours analysed interestingly showed inactivating 
mutations in Notch1 receptor. Activating mutations were however demonstrated in 
the larger subset with increased expression or increase in gene copy number of 
receptors and ligands, and increased downstream pathway activation197. In a “whole 
exome” and transcriptome sequence experiment, to characterise alterations in Notch 
genes in early-stage (T1-T2) tongue squamous cell carcinomas (TSCC), in which 29 
patient-derived tumour samples were used, Notch pathway was shown to be indeed 
activated in TSCC patients202.  A bimodal mutation pattern was also observed, but 
unlike the study previously described, a lower inactivating Notch1 mutation of 4% 
was characteristic. A consistently higher frequency level of activating mutation was 
observed in 59% samples (17 of 29 patients). These activating mutations were 
observed in all the components of the Notch pathway including receptors, ligands 
and downstream target genes202. Importantly, in the same study, Notch1 was shown 
to be essential for survival, migration and stemness of TSCC tumour cells202. In 
another study to characterise the expression of transcriptionally active Notch1 
intracellular domain (NICD1) in HNSCC, using immunohistochemical (IHC) approach, 
the cleaved Notch1 was shown to be associated with HNSCC high risk factors, in 
addition to its being highly expressed in HNSCC199. In the study, IHC was performed 
to analyse the distribution / expression of the cleaved Notch1 using 79 already 
sequenced HNSCCs whose mutation status were already determined. NICD1 was 
shown to be indeed associated with mutation status (p<0.001), and most 
interestingly, positive staining was observed in a combined 81% of the samples, with 
the remaining 19% recording negative stainings199. 58% of the positive stainings were 
characteristically peripheral, while the remaining 42% were non-peripheral. The high 
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level of NICD1 expression does signify increased Notch activation, and the fact that 
the general expression was in association with mutation status does indicate that the 
mutation was more of an activating, rather than inactivating type199.  
 
1.9.3 Correlation of increased Notch signalling with prognosis and tumour 
aggressiveness   
 
High expression levels of Notch1 are thought to confer poor prognosis in HNSCC, with 
results obtained from correlation of Notch1 expression levels, with levels of 
resistance to Cisplatin, which is considered the main chemotherapeutic agent for the 
treatment of HNSCC203 (p=0.000). Upregulation of Notch pathway was also shown to 
correlate with increased patient mortality200. It also correlated with increased 
expression of FGF1, which is a pro-invasive gene, with in vitro activation of Notch in 
HNSCC cells leading to increased transcription of FGF1200. This in turn was shown to 
induce an obvious increase in both cell migration and invasion, with subsequent FGF1 
knock-down bringing about an abrogation of the increased migratory and invasive 
effects initially associated with over-expression200.   
 
1.9.4 The contradictory evidence for Notch as a tumour suppressor and / or 
oncogene    
 
It is still debateable if its main role is oncogenic or as a tumour suppressor, or if down-
regulation rather than its up-regulation is key for the formation of cancer. Its actual 
role has also been shown to depend on the cancer type or setting204.   
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It is proposed that, while some members of the Notch family are considered more of 
tumour promoters, others may be classified as tumour inhibitors. Indeed, there have 
been cases where the same Notch subtype has been ascribed opposite roles by 
different researchers, as highlighted below. This is not coming as a surprise, 
considering the opposite roles Notch actually plays in developmental processes 
where it enhances stem cell potentials on one hand with a suppression of 
differentiation, while on the other hand it promotes differentiation and commitment 
to other cell/tissue lineages205. Overall, Notch has been repeatedly linked with the 
pathogenesis of head and neck cancers. 
A recently published work has also suggested that down-regulation of the Notch4 
gene is associated with recurrence in cases of OSCC (oral squamous cell carcinomas), 
with a p-value of 0.001193. Priority is now placed on better understanding of the Notch 
signalling pathway which entails rather complex molecular alterations of the 
pathway. In the study by Wenyue et al. the possible activation of Notch signalling 
pathway in HNSCC (head and neck squamous cell carcinomas) was investigated194. In 
that study, the mRNA expression of HES-1 and HEY-1 was significantly higher in 
HNSCC tumours than in normal mucosa, having used a cohort of human tissue 
samples comprising of tumours (n=44) and paired normal (n=25). Using expression 
array analysis, they were able to demonstrate that JAG1, JAG2 and NOTCH3 genes 
were overexpressed in tumour compared to normal tissues, therefore signifying 
possible up-regulation of notch in HNSCC. This is somewhat in contrast with an earlier 
report by the same investigators198. They also found out that a total of 31.8% of 
HNSCC tumour samples examined showed over-expression of HES1 and/or HEY1 
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genes. Findings were further validated using an independent cohort of HNSCC 
samples along with a set of normal tissues, using quantitative RT-PCR. Significantly 
measured expressions of the two genes HES-1 and HEY-1 were found in HNSCC as 
against normal tissues194. In general, experimental reports in favour of an oncogenic 
role for Notch are more, however, reports are available as shown, where down-
regulation of Notch has been attributed to tumorigenesis, thus ascribing to it a 
tumour suppressor role206.  
Notch 1 has been shown to play a tumour suppressor role in neuroendocrine tumours 
in a study where activation of the same notch subtypes did correlate with down 
regulation of tumour markers specific for the tumour type207. In another study using 
lung cancer cell lines and mouse models, investigators were able to demonstrate 
opposing roles for Notch1 and Notch2, with Notch2 deletion resulting in increased 
carcinogenesis, suggesting a tumour suppressor role204. Notch 1 was shown to play a 
tumour suppressor role in skin cancer by another group of investigators, with a 
knockdown of Notch 1 leading to the development of skin cancer following epidermal 
hyperplasia208. Notch signalling was shown to induce cell cycle arrest in small cell lung 
cancer cells209. These, and the previously well highlighted examples suggest indeed 
that Notch could act on both sides of the divide, as tumour suppressors or 
“promoters”.   
Two proteins, ADAM17, and iRhom2, are believed to be involved in the biochemistry of signal 
transduction by notch, with ADAM17 proposed to be responsible for the S2 cleavage in the 
Notch signalling system210. This S2 cleavage which occurs at an extracellular site and between 
Ala (position 1710) and Val (position 1711) residues results in the production of NEXT (Notch 
Extracellular Truncation)211,212. This is despite the fact that ADAM10 is commonly credited 
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with being the principal sheddase of Notch213. ADAM17 and iRhom2 are discussed 
shortly.   
 
1.10 Consequence of the development of cancer 
 
A notable consequence of the development of cancer is believed to be alterations or 
deregulation of growth signalling pathways in cancer cells214, with cancer cells now 
known to adopt a means by which they are able to set up an autocrine production of 
essential growth factors, maintained by an organised positive feedback mechanism 
independent of their environment215. The rhomboid proteins (particularly iRhom2), 
are an emerging, newly identified class of proteins thought to be involved with 
trafficking and regulation of other proteins, and now implicated in the pathogenesis 
of a number of cancer types including; oesophageal cancer216, head and neck 
cancer217 and ovarian cancer218. The iRhoms, a subset of the rhomboid family have 
been evidently linked with trafficking/activation of very important growth and 
signalling factors such as TACE (tumour necrosis factor α convertase)219, EGFR216, and 
TGFα (transforming growth factor α)220. Of uppermost interest in this study is the link 
between the iRhom2 protein and the sheddase TACE/ADAM17, which is already 
known to be important in the shedding activities and subsequent activation of notch, 
thought to be an oncogene194. 
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1.11 ADAM17: 
 
The ADAM family of proteins has been widely studied and members are thought to 
be key players in the activation/deactivation of proteins by a process known as 
shedding, an important regulatory process which remains poorly understood despite 
its importance221.  The process of shedding involves proteolytic cleavage of proteins 
and a subsequent release of their ectodomain222. This important molecular 
mechanism could also result in a change in the functional properties of the affected 
proteins223, and other metalloproteases such as members of the matrix 
metalloproteases (MMP) family have also been implicated224 in this role. Sheddases 
are therefore generally able to regulate cell activities by directly shedding membrane 
receptors or indirectly, through soluble mediators arising from the shedding of other 
membrane bound inactive precursors or ligands225. Most of this shedding process is 
reported to take place on the cell surface and the surface expression of the protein 
has been reported to be tightly regulated226. Most of the protein in its immature, and 
therefore inactive form is stored intracellularly, with only a fraction of the eventual 
mature / activated form demonstrated to be available on the cell surface227-229. 
Numbered according to order of discovery, 22 members of the ADAM family of 
proteins have been identified in the human genome, with a dozen encoding active 
enzymes230. Structurally, they are made up of an N-terminal, a pro-domain, a 
metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like 
domain, a transmembrane domain and a cytoplasmic domain231 (Figure 1.15). The N-
terminal consists of a signal sequence which directs the enzyme into the secretory 
pathway in the first instance232,233. The pro-domain serves as the inhibitor of the 
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enzyme, maintaining it in an inactive form. This is therefore cleaved off in the trans-
Golgi apparatus to render the enzyme active234-236. The metalloprotease domain, 
which contains a zinc ion chelating sequence, is also known as the catalytic domain 
and is responsible for the actual shedding or proteolytic activity of the enzyme237.  
 
 
 
 
Figure 1.15  Structure of a typical ADAM protein showing its various components.  
It comprises of a large extracellular part and a smaller intracellular part. The 
extracellular part comprises of the domains such as the Metalloprotease, Disintegrin 
and EGF-like domains, and the Cysteine-rich part. The intracellular part is made up of 
the Cytoplasmic domain. 
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The disintegrin domain contains a 14-amino acid sequence also referred to as the 
disintegrin loop, responsible for the interaction between the enzyme and 
integrins236,238. Example of such interactions is with α₅β₁, with both molecules co-
localising in HeLa cell membranes239. The cysteine-rich domain is associated with cell 
adhesion and fusion, and possibly interacting with ECM (extracellular matrix) and its 
vital constituent molecules, necessary for control of cellular activities, as well as cell 
to cell adhesion / interaction230. The cytoplasmic domain is shown to interact with 
proteins involved with intracellular activities such as trafficking, signalling and the 
maintenance of cell structure. Therefore, though primarily sheddases, the ADAMs 
also play other important cellular roles236,240,241. Functions of the EGF-like domain 
which is absent in ADAM17 and ADAM10 remain largely unknown241.   
 Now thought to be expressed in a variety of cells/tissues and organs242,243, their 
activities have also been shown to be quite diverse, ranging from sperm-
interactions244 to cell fate determination in nervous system236. Other functions 
include cell migration, muscle development and various aspects of immunity236. Here, 
focus will be on an important member of the family, ADAM17, also known as TACE 
(Tumour Necrosis Factor-α converting enzyme) whose activities are related to and 
somewhat similar to those of another member of the family, ADAM10. 
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1.11.1 Roles of ADAM17 
 
Roles of ADAM17 have been investigated and documented to be indeed diverse. It is 
involved in the shedding of proteins, many of which are important signalling 
molecules such as TNFα, TGFα, EGF, HB-EGF, and VEGFR2, and adhesion molecules 
such as L-selectin, syndecans, CAMs (Cell Adhesion Molecules) and cadhesins245-247. 
Some of these molecules are largely involved in the regulation of cell proliferation, 
survival, migration and invasion, and thus may have implications in the development 
of cancer. These properties are often a result of the crosstalk between ADAM17 and 
epidermal growth factor receptor (EGFR)231,248, and the Notch pathway249, both of 
which have been linked with head and neck cancers. EGFR, a notable member of the 
ErbB family of receptors is widely known for its inherent ability to stimulate epithelial 
cells, causing them to proliferate250, and is now thought to be an oncogene of head 
and neck cancers251. Using a 250k single nucleotide polymorphism array for analysis 
of subchromosomal alterations in OSCC, Jim Sheu et al were able to demonstrate the 
most frequent amplification in HNSCC to be that at 7p11.2 (in about a third of the 
cases), and this contains the EGFR. They also showed EGFR to be the most frequently 
amplified and highly expressed gene among the ErbB family, using both human and 
mouse oral cancers. The pattern of up-regulation of EGFR in oral cancer was further 
verified using immunofluorescence analysis and fluorescence in situ hybridization251. 
This data is in addition to data from several other studies which have implicated EGFR 
signalling in the pathogenesis of HNSCC252-256, tagged it a possible prognostic / 
diagnostic / predictive biomarker257-260, and shown the importance and effectiveness 
of targeting it (especially as a co-target) for therapy261-264.  
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Several investigations have demonstrated up-regulation of ADAM17 in cancer, and 
the level of expression appears to correlate with tumour aggressiveness and rate of 
growth246,265-270. It is therefore gradually becoming a potential prognostic biomarker 
in a number of cancer types271. The exact role played by ADAM17 and its mechanism 
of operation has been shown to vary, functioning in both tumour formation and 
progression via proteolytic and / or adhesive properties272. Its metalloprotease and 
disintegrin domains are responsible for shedding and adhesion properties 
respectively231. 
In a study using OSCC (oral squamous cell carcinoma) cell lines and orthotopic murine 
tumour models, Simabuco et al were able to demonstrate that ADAM17 
overexpression interferes in the biological processes associated with tumorigenesis 
of oral cancers273. In that study, ADAM17 overexpressing cells were subjected to in 
vitro functional studies, and injected into the immunodeficient mouse models with 
MS-based proteomics of resultant tumour tissues. Increases in tumour size, migration 
rate, invasion (measured via level of tissue collagenase activity), viability and 
adhesion were all demonstrated with increased expression of ADAM17246. 
Observations from mass spectrometry based proteomics in which several Erk 
regulatory proteins were found to be up-regulated in the tumour tissues from the 
mouse models give credence to suggestions ADAM17 also has a downstream 
molecular regulatory effect in addition to phenotypic role it plays. This will however 
require further research, considering the Erk pathway is downstream of EGFR as well, 
and thus may just be as a result of increased EGFR signalling via increased EGF or TGF 
release. 
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  In another study on renal cancers by Franovic et al, ADAM17 was shown to be key 
in enabling tumour cells acquire survival capabilities such as migratory and invasive 
properties, as well as growth autonomy and tumour inflammation274. Using mouse 
models, In vivo formation of originally highly malignant renal carcinoma tumours was 
demonstrated to be sufficiently suppressed through silencing of ADAM17. 
Mechanism of operation of ADAM 17 was proposed to be via making available soluble 
TGF-α which in turn is an EGFR ligand274. 
In their study on breast cancer, using the breast cancer cell lines MCF-7 and MDA-
MB-435, McGowan et al reported increased in vitro invasion and proliferation of 
cancer cells with overexpression of ADAM17, and a decrease in these processes with 
down regulation of ADAM17275. In this study, using ELISA and western blot techniques 
on a set of tumour samples, a relationship was shown to exist between ADAM17 
levels and standard prognostic factors for breast cancer. High grade carcinomas had 
significantly higher concentrations of ADAM17 (p=0.017) compared to the lower 
concentrations in low grade carcinomas. Also, poor overall survival was associated 
with higher concentrations of the protein275. 
 Suppression of ADAM17 function either through decreased expression of the protein 
or through inhibition of its protease activity, was shown to reverse the malignant 
phenotype using 3D culture models of human breast cancer cells by Kenny and Bissel. 
The inhibition resulted in reduced growth of the cell lines and reversal of their 
features similar to those of non-malignant cells. This reversal of morphological 
features was absent where there was overexpression of soluble pre-cleaved mutants 
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of AREG or TGF-a, but not the case with full length AREG or TGF-a. This thus suggests 
a role for ADAM17 in the early stages of malignant transformation276. 
 Also, in a study by Zhang-Xuan et al to evaluate the clinical significance of ADAM17 
in the progression and prognosis of gastric cancer, the protein was found to be up-
regulated in tumour lesions compared to adjacent normal tissues277, making it a 
potential biomarker. 
The experiments and studies highlighted have overwhelmingly supported the 
proposition that ADAM17 plays an oncogenic role in the pathogenesis of a wide 
variety of cancer types. Highly likely to be involved in both formation and progress of 
tumours, primarily as a result of its key role in the proteolytic cleavage of an array of 
proteins.     
As mentioned earlier, ADAM17 is also known as TACE (TNF-α Converting Enzyme), 
due to its important role of releasing the active form of TNF-α from its precursor. The 
release of TNF-α, and the associated inflammation in turn has been directly 
implicated in liver, intestinal and ovarian cancer278-282. These studies as well as many 
more have been able to provide strong evidence that ADAM17 plays a role in the 
formation and progression of cancer. 
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1.12 ADAM17, iRhom2 and cancer 
 
In an experiment by Colin Adrian et al, utilising in vitro differentiated macrophages 
from the bone marrow of mutant mice, loss of TNF shedding with the loss of iRhom2 
was shown to be responsible for a complete abolition of activity of TACE219; the 
protein, iRhom2 already established to be predominantly expressed in macrophages. 
Inhibition of TACE in wild type cells (macrophages) by the matrix metalloproteinase 
inhibitor BB94 gave rise to a phenotype similar to iRhom2‾′‾ macrophages, implying 
a shedding defect with the loss of iRhom2219. Overall, they investigated the regulation 
of ectodomain shedding by genetic and cellular approaches in both Drosophila and 
mammalian cells, generating null mutations in RHBDF2 which encodes for the 
iRhom2 protein. Firstly, the resultant iRhom2‾′‾ (Knock out) mice appeared normal. 
To mimic inflammation, where among other cytokines TNF was expected to be up-
regulated, the iRhom2‾′‾ mice were challenged with lipopolysaccharide (LPS) 
stimulation, but TNF induction was nevertheless observed to be almost completely 
abolished in the mutant mice. Equally, in vitro differentiated bone marrow derived 
macrophages (macrophages being the major sources of TNF) from iRhom2‾′‾ mice 
failed to secrete TNF in response to LPS. With RNA levels of TNF unaffected, and 
protein levels actually elevated in iRhom2‾′‾ mice, it was not a lack of expression, 
but rather a shedding defect. 
These findings therefore implied that loss of iRhom2 as with the mutant mice does 
not interfere with the induction or with the intracellular trafficking of TNF, rather, it 
suggests a defect in the shedding process necessary for its eventual activation. Also, 
to show that the impact of iRhom2 on TACE has to do with trafficking to its site of 
 79 
 
action, already established to be the membrane, TACE was found to be absent on the 
surface of iRhom2‾′‾macrophages in contrast to WT cells. 
Equally, in the absence of iRhom2, TACE never became endo-H resistant, 
demonstrating the fact that it was never able to reach the Golgi, which further points 
at a defect in trafficking. They therefore concluded that, while trafficking from the ER 
is a limiting step for TACE maturation, iRhom2 is also an essential component of the 
biological mechanism that functions to release it to the Golgi apparatus. In the 
absence of iRhom2 therefore, TACE will not reach the Golgi apparatus to become 
activated. To examine these findings directly, mouse iRhom2 was expressed in 
human embryonic kidney (HEK) cells, with its effect on endogenous human TACE 
assayed. It was observed that overexpression of iRhom2 caused excess TACE to leave 
the ER which resulted in more furin-processed TACE, and thus an overall increase in 
TACE enzymatic activity219. The rhomboid-like proteins are hereby discussed, with 
emphasis on iRhom2. 
 
 
1.13 The rhomboid-like proteins:  
 
1.13.1 The rhomboid-like family of proteases.  
 
It is the systematic exploration of Drosophila EGFR and the important roles it plays in 
a variety of intracellular events that led to the discovery of the rhomboid family of 
proteases283, now known to be the main activators of the EGFR signalling pathway in 
this organism284,285. The activation process was initially thought to be only via direct 
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interaction with the main EGFR ligand, Spitz (a TGFα-like protein), but additional 
ligands and functions / mechanisms are now thought to be highly likely286,287. More 
recently, several studies have turned their focus on these other possible adjuvant 
roles for the rhomboid proteases apart from the traditional growth factor signalling 
role.  Rhomboids are intramembrane serine proteases (IMP), with their active and 
catalytic residues buried in the lipid bilayer of the cell membrane (Figure 1.16). This 
localisation of their catalytic region enables them to easily cleave or activate / 
inactivate membrane proteins within their transmembrane helices (TMH)288, 6 in 
prokaryotes and 7 in eukaryotes, in a two-step process, docking and scission. It is 
important to note however that, outside their catalytic/active site, other substrate-
rhomboid interactive sites known as exocites have been described289,290, and in 
substrate binding, the initial docking or interrogative step is shown to take place at 
the exocites.  
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Figure 1.16  traditional rhomboid protein illustration: 
Schematic illustration of a traditional rhomboid protein, showing the seven 
transmembrane helices (TMH) connected by loops. Both serine (S) and histidine (H) 
residues which make up the catalytic centres are shown on the fourth and sixth TMHs 
respectively, with their helix dimerization GxxxG sequences, important for structural 
stability. Between the first and second TMHs is the relatively long L1 loop which also 
houses the W/xR sequence.  
 
 
Apart from the active core buried mostly in the membrane, most rhomboids in 
addition contain N- or C-terminal accessory regions outside the membranes. These 
accessory regions may function as extra exocites, an example is the extra ubiquitin 
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interacting motif (UIM) associated with RHBDL4 and found in its cytosolic region291. 
Peculiar with all rhomboid-like proteins is a rhomboid fold which consists of six or 
seven TMHs. In eukaryotes, a seventh TMH is added either at the C-terminal or the 
N-terminal, giving rise to a 1+6 TMH in the case of an addition to the N-terminal, or 
6+1 TMH with the addition at the C-terminal292. These are referred to as the topology 
classes or topology classification. The active centres are the serine and histidine 
residues, located in the fourth and sixth TMH respectively (Figure 1.16), and this is 
known as the catalytic dyad, different from the classical catalytic triad of (D-S-H) 
common with other soluble serine proteases292-294. C-terminal addition is common 
with rhomboids in the secretory pathways, and N-terminal addition is localised to 
organelles such as mitochondria rhomboids. Five rhomboid-like proteases named 
RHBDL1-4 and PARL (Presenilins-associated-rhomboid-like), and a group of nine 
pseudoproteases make up the broad super family of rhomboid-like proteases. 
The catalytic centres mentioned earlier are highly conserved in all rhomboids except 
the inactive pseudoproteases with the catalytic centres somewhat mutated295-297. 
Crucial for rhomboid structure stability is the helix dimerization GxxxG sequence. This 
is also highly conserved in rhomboids (active and inactive), possibly due to its 
importance in maintenance of rhomboid stability292,298. Another highly conserved 
motif in active rhomboids is the short W/xR sequence, situated in the rather long L1 
loop between TMH1 and TMH2288. The long L1 loop is thought to be key in 
maintaining structural integrity in active rhomboids.   
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1.13.2 RHBDL1, 2, 3 & 4 and PARLs.  
 
RHBDL1-4 are active in the secretory pathway, while PARLs, localised to the inner 
mitochondria membrane where they cleave mitochondria membrane bound 
proteins, and are thus involved with the overall homeostasis of the mitochondria299. 
A number of substrates/targets have been identified for PARL and RHBDL4, but not 
RHBDL1,2 & 3 which remain only poorly characterised300,301. RHBDL2 has been shown 
to effectively cleave proEGF for subsequent activation of EGFR signalling302. ADAM17 
and ADAM10 are traditionally known for the above role303, therefore, we hypothesise 
that the process by which RHBDL2 cleaves proEGFR might be an alternative pathway 
necessary in case of low supply of the primary sheddases. Increased activation of the 
EGFR pathway is known to be associated with cancer, thus implicating the rhomboid 
proteases in cancer formation or progression via the EGFR activation pathway. 
Indeed, overexpression of RHBDL2 has been shown to correlate with increased cell 
proliferation and resistance to anoikis in malignant epithelial cells304. Loss of cell 
proliferation in the form of reduced wound healing has also been demonstrated with 
loss of RHBDL2305, and this may be due to a reduction in one of RHBDL2 substrates – 
soluble thrombomoduline306. Although the molecular mechanisms of carcinogenesis 
are under discussion and indeed remain unclear, RHBDL4 has been implicated in 
several cancer types, including colorectal cancer307,308, liver cancer309, and 
glioblastoma310. This Rhomboid protein is generally known to be localised to the ER291 
where it is primarily involved with ER-associated degradation (ERAD).      
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1.13.3 Rhomboid pseudoproteases.  
 
These include iRhoms (iRhom1 and iRhom2) and Derlins, and have been shown to 
influence the fate of their targets by playing key roles in their intracellular trafficking 
or degradation311. It has been suggested that the inactive rhomboids have arisen 
from repeated duplications of the active rhomboids followed by diversification and 
loss of function311,312. iRhoms are the inactive homologues of rhomboids and are 
structurally different from their active counterparts in that they lack the traditional 
active residues, and contain both an extended cytoplasmic amino acid terminus as 
well as a Cys-rich luminal loop domain (iRhom homology domain) between TMH1 and 
TMH2313 (Figure. 1.17). Two iRhoms, iRhom1 (RHBDF1) and iRhom2 (RHBDF2) have 
been identified in mammals. 
 
 
1.13.4 iRhom2.  
 
iRhom2 has been shown to be highly expressed in macrophages and involved with 
the intracellular trafficking of other proteins, ADAM17 a notable example219. iRhom2 
has been directly linked with disease conditions such as tylosis and oesophageal 
cancer216, and in epithelial ovarian cancers218.     
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Figure 1.17  Structure of an iRhom showing its TMHs: 
Structure of an iRhom showing its TMHs (TMD – Transmembrane domains) 
arranged between its two terminals, C and N. 
 
 
Recently, experiments in mice have shown that iRhom2, a proteolytically inactive 
member of the rhomboid-like family of proteins, is required for the trafficking and 
maturation of TACE219 (ADAM17). Produced in the Endoplasmic reticulum, TACE 
acquires its maturation in the Golgi apparatus where its pro-domain part is removed 
by a furin-type PRO-PROTEIN convertase or by autocatalytic removal, and iRhom2 is 
an important component of the mechanism responsible for its release into the Golgi 
apparatus219,314,315. 
Independent of the ADAM metalloproteinase pathway, EGF has also been shown to 
be directly regulated by iRhom1 and iRhom2 in COS-7 and HeLa cells, with both 
proteins being co-precipitated with FLAG-tagged EGF. This direct effect was shown to 
occur via ERAD (ER-associated degradation), with ADAM family proteins inhibited in 
 86 
 
the experiment316. The cleavage of EGF (Myc-tagged) by iRhom2 with subsequent 
activation of the EGFR pathway has also been reported317. Taken together, this will 
suggest that, apart from EGFR activation via iRhom2 and ADAM17 partnership, the 
same activation of EGFR might occur with the aid of iRhom2, and in the absence of 
ADAM17, following a different pathway. ADAM17 therefore cannot be considered 
indispensable for EGFR signalling, considering the availability of an alternative 
pathway. EGFR signalling is known to be very vital in developmental processes, and 
has been repeatedly shown to be deregulated in several cancers including breast 
cancer318, lung cancer319, pancreatic cancer320 and oral cancer321. Furthermore, 
Blaydon’s report showed that keratinocytes, from individuals with a mutated form of 
iRhom2 were unaffected in terms of wound healing potential when starved of 
exogenous EGF322. This was proposed to be due to a sustained endogenous delivery 
of the growth factor in the presence of up-regulated iRhom2216. This missense 
mutation in the gene RHBDF2, which codes for iRhom2, is the underlying cause of 
tylosis, an autosomal dominant inherited condition which is associated with familial 
oesophageal cancer216 and mutations in the same region of RHBDF2 has been 
reported in other familial oesophageal cancer323. 
 
1.14 Conclusion 
 
Aside the original link with EGFR signalling which did herald its discovery (rhomboid-
like family of proteases in general)283, it is becoming quite evident that the rhomboid 
protein, iRhom2 is a major influence in the eventual shedding role of the very 
important sheddase, ADAM17219. Also, ADAM17 being an important sheddase in the 
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activation of the Notch signalling pathway324 makes the cellular partnership between 
ADAM17 and iRhom2 entirely vital for signal transduction of Notch, and possibly a 
few others. 
If up-regulation or indeed down-regulation of Notch is proven to be linked with 
carcinogenesis, there could be corresponding increase or decrease in expression 
levels or activities of ADAM17 and iRhom2 in such cancer cases. 
Currently, there is sufficient data to suggest that ADAM17 is associated with 
HNSCC273. Data is equally gradually building up to indicate that iRhom2 is upregulated 
in HNSCC, and that iRhom2 is vital in the intracellular trafficking of ADAM17, while 
also favouring its activation / maturation325. However, little experimental work has 
been carried out in clinical tissues, nor has the expression of the protein been 
correlated with clinical outcome. ADAM17 and its close relative, ADAM10 have 
already been known to traditionally cleave Notch to enhance its activation213. There 
exist some controversy with regards to an entirely oncogenic role for Notch in 
HNSCC197, but there is robust data in favour of an oncogenic role. Importantly, studies 
have shown reduced carcinogenesis with downregulation of ADAM17 and iRhom2, 
using mouse models219. Putting all of the available data together, it may be suggested 
that the oncogenic role of Notch is enabled by the shedding activity of ADAM17, 
which is further made possible by the intracellular trafficking afforded by the 
rhomboid protein, iRhom2 (Figure 1.18). This therefore leads to our working 
hypothesis that, Increased expression of iRhom2 in oral cancer cells, through its 
interaction with ADAM17, contributes to tumorigenesis in this cancer type. 
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Aim: To demonstrate that iRhom2 controls ADAM17 expression in HNSCC and that 
this contributes to tumour pathogenesis. 
 
Objectives: 
 To show that expression of iRhom2 and ADAM17 proteins is altered in HNSCC 
tissues and is associated with clinicopathological features suggestive of 
tumour aggression. Two cohorts of clinical tissues with clinical, pathological 
and outcome data will be assayed by western blot and 
immunohistochemistry. 
 To demonstrate that iRhom2 controls the expression of the mature form of 
ADAM17 at the cell membrane in HNSCC. A series of in vitro experiments will 
investigate the consequence on ADAM17 expression, of up- and down-
regulation of iRhom2. 
 To investigate the effect of changes in iRhom2 and ADAM17 expression on 
HNSCC cell phenotype. Functional analysis of HNSCC cell lines will explore the 
effect of altered iRhom2 and ADAM17 expression on tumorigenic 
characteristics such as proliferation and migration.  
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Figure 1.18  Diagram illustrating the binding of a notch ligand to initiate a proteolytic 
cascade. The signalling cascade is shown to involve iRhom2, ADAM17 (TACE) and 
Notch. Synthesised ADAM17 is trafficked by iRhom2 from point of synthesis, ER 
(Endoplasmic Reticulum), to the Golgi for maturation, and eventually to the cell 
membrane where it is involved with Notch activation. Notch activation is seen to lead 
to the release of an intracellular fragment – red arrowhead, NICD (Notch intracellular 
domain), which translocates into the nucleus for downstream target activities. 
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2 Chapter 2: Materials and methods 
 
 
 
 
2.1 Introduction 
 
This study was split into two main parts. Investigations with the use of clinical specimens in 
form of tissue samples (tumour and paired normal), and scoring of TMAs (tissue microarray) 
was accommodated in the first part of the experiment, while the second involved the use of 
cell lines and determination of cellular functional changes following transfection. 
  
2.2 TMA (tissue microarray) scoring and analysis. 
 
A cohort of oral cancer and adjacent normal tissue from 122 patients had been used 
previously to construct two TMAs containing triplicate cores326. These TMAs were 
stained immunohistochemically using standard methods on a DAKO autostainer 
(Dako, Ely, UK), using its proprietary kit, the Dako EnvisionTM FLEX/HRP Detection 
system. In brief, a high temperature antigen retrieval method was employed using 
the DAKO PT-Link system (Dako, Ely, UK) on 4μm sections of the TMAs and final 
dilutions of 1:300 anti-iRhom2 antibody (Prestige HPA018080, Sigma-Aldrich, Poole) 
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and 1:150 anti-ADAM17 antibody (ab2051, Abcam, Cambridge). Primary antibody 
was omitted from negative controls. IHC stained TMA blocks were analysed 
(consensus reporting by two observers), using a semi-quantitative method for scoring 
intensity of immunoreactivity, and graded: + (weak staining), ++ (moderate staining) 
and +++ (strong staining). Tumour, CAFs (cancer associated fibroblasts) and 
inflammatory cells were all scored according to their levels of staining. For statistical 
analysis and correlation with available clinicopathological data, only oral cancer cases 
were included, with oropharyngeal cases excluded, giving a total of 100 oral cancers.  
 
2.3 Tissue collection:  
 
Fresh, frozen tumour specimens were obtained from a total of 99 HNSCC patients, 
whose primary treatment was surgery, together with paired normal tissue taken from 
the tumour margins of 38 patients. Written consent was obtained from all patients 
and in accordance with the laws governing tissue collection, storage and use in the 
UK (REC numbers: EC.47.01 & 10/H1002/53). Tissues were snap frozen in liquid 
nitrogen before being transferred to -80®C for longer storage. 
 
2.3.1 Analysis of tissue composition:  
 
Tissue from each frozen specimen was embedded in OCT (CellPath Limited). Two 5μm 
sections were taken for H & E staining and for subsequent histopathological 
assessment of degree of tumour content by a consultant oral pathologist. Staining 
was carried out at room temperature thus: 
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 Paraffin wax was removed by incubating in xylene for 5 minutes (step 
repeated with fresh xylene) 
 Incubate in absolute alcohol for 5 minutes, followed by 
 70% alcohol for 5 minutes and 
 50% alcohol for 5 minutes 
 Incubated in haematoxylin (Thermo Scientific) solution for 5 minutes 
 Washed under tap water for 2 minutes 
 Dipped in acid alcohol 3 times 
 Rinsed under running water 
 Incubated in eosin (Thermo Scientific) solution for 15 seconds 
 Washed in tap water 
 Dehydrated thus: 
 Incubated in 70% ethanol for 5 minutes (repeated using fresh ethanol), 
followed by 
 90% alcohol twice and then absolute ethanol twice 
 Incubated in xylene for 5 minutes and then 
 Mounted in DPX (Fluka) solution and coverslipped. 
Tumour samples with less than 50% tumour cells in either of the 5µm sections were 
excluded from the cohort. Normal samples with more than 5% tumour cell content 
on either of 5µm sections were also excluded from the study. Also excluded, tumour 
or normal tissues, were those predominantly fibrous, bony or fatty tissues (Appendix 
1). 
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2.3.2 Protein extraction and quantification.  
 
5mm³ pieces of tissues were excised from each sample, using disposable scalpels and 
targeting areas with an increased number of tumour cells or lack of tumour as 
appropriate. Harvested tissues were resuspended in 300μl of protein extraction 
buffer (50 mM Tris–HCl, pH 6.8, 1% SDS, 1% EDTA, 0.25% glycerol, 0.25% β-
mercaptoethanol) with protease inhibitor (Roche Diagnostics), and total protein was 
extracted with the use of a sonicator (Sonics and materials INC, 40-50 amplitude for 
30 seconds). Extracted protein was stored in aliquots at -80ᵒC until use. Total protein 
was quantified using the Bradford assay. 
 
2.4 Western blot analysis.  
 
2.4.1 Electrophoresis and electroblotting:  
 
40µl of protein preparation containing between 20μg and 50μg of total protein were 
mixed with a half volume of sample loading buffer and boiled for 5mins prior to being 
loaded unto 10% SDS/PAGE gels (Appendix 2). Electrophoresis was carried out at 
60mV / 34mA for 16 hours. TE3-IR2+, an oesophageal cancer cell line constitutively 
expressing iRhom2, was used as a positive control.  
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Following electrophoresis, gels were transferred to 0.45μmm PVDF membranes (GE 
Healthcare Life Sciences) and electroblotting carried out for 4 hours at 80mV / 
350mA. 
 
2.4.2 Antigen detection:  
 
Prior to probing with primary antibodies, blocking of membranes was carried out for 
one hour at room temperature using blocking solution (PBS + Licor Blocking Buffer, 
ratio 1:1), and the incubated membranes placed on a rocker. 
The following primary antibodies were incubated at 4ᴼC overnight; rabbit-anti-
RHBDF2 (1:500: Sigma Aldrich HPA018080-10CUL), goat-anti-ADAM17 (C-terminal, 
1:350: Santa Cruz, sc-6416 and N-terminal, 1:350: Santa Cruz, sc-13973) and mouse-
anti-β-Actin (1:1000: Santa Cruz, sc-47778). Membranes were washed in PBS (with 
2% Tween20, Sigma Aldrich), for 5 minutes x 3 rounds, prior to incubation in 
secondary antibody. Fluorescent secondary antibodies; IRDye@800 (goat anti-
mouse, 926-32210, and goat anti-rabbit, 926-32211, both Licor) and Alexa Flour@680 
rabbit anti-goat, A21088, were used at a concentration of 1:10,000 for 2 hours 
incubation at room temperature. 2% Tween20 (Sigma Aldrich) was added to the 
blocking solution and used to dilute the primary and secondary antibodies. 
Components of running buffer and transfer buffer are shown in Appendix 3. 
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2.4.3 Analysis of results 
 
At the end of both primary and secondary antibody incubation, membranes were 
rinsed in 1 x PBS solution, three times for 5 minutes in each case. The membranes 
were scanned and visualisation of fluorescent secondary antibody localisation was 
undertaken on a Licor Odyssey scanner (3.0 Model).  
Densitometry was used to normalise and semi-quantitate the levels of protein 
expression in comparison with the actin control. Briefly, the intensity of the β-Actin 
band in each lane was measured and a ratio of control intensity divided by sample 
intensity was created. This ratio was used to normalise the iRhom2 and ADAM17 
protein expression levels thus: 
 
 
2.5 Normalisation  
 
Densitometry was used to normalise and semi-quantitate the levels of protein 
expression in comparison with the actin control. Briefly, the intensity of the β-Actin 
band in each lane was measured and compared to that of the positive control, TE3. 
The ratio obtained was used to derive a correction factor (how many times more the 
B-Actin of the control band is) (Figure 2.1). Multiplying the correction factor by the 
densitometry of the target band gives a value that indicates the level of expression 
(status) (Figure 2.1). Status of High, Moderate and No expression were ascribed 
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based on the cut-off (a choice of 75th percentile / upper quartile – shown in section) 
from the cumulative frequency curve of the data (Figure 2.1 & Figure 3.5). 
 
 
 
Figure 2.1 Western blot normalisation: 
Illustration of how the β-Actin values of individual samples were used to obtain a 
correction factor, in reference to a standard, in this case the positive control (TE3-
wild type, an oesophageal cancer cell line). Eventual densitometry score for each 
sample, a product of correction factor and iRhom2 value (a X b), and expressed in 
percentage with reference to the control value, was graded. Grading/Status 
expressed as colour codes to represent over-expression (dark orange), normal 
expression (light orange), and non-expressing (white), were based on cut-off values 
of 11 and 20.     
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2.6 Peptide blocking / competition studies 
 
 
This was done to determine iRhom2 and ADAM17 (mature and immature) bands of 
interest and differentiate such from non-specific bands. The cancer cell line, PE/CA-
PJ15 was used, due to its high level of baseline expressions of both iRhom2 and 
ADAM17 proteins. The western blot experiment described in section 2.4 was 
followed, with two identical gels, containing the same protein lane arrangement. For 
antigen detection described in section 2.4.2, incubation of one of the identical 
membranes followed the exact protocol, with the second membrane having its 
primary antibody incubated in its complementary blocking peptide for four hours at 
room temperature prior to membrane incubation. Anti-iRhom2 antibody (Abcam, 
ab116139) already constituted at 1:500 in its antibody solution, and its 
complementary blocking peptide (Abcam, 216174) were mixed at 50:1 ratio by 
volume. Anti-ADAM17 antibody (Santa Cruz, sc-6416) already constituted at 1:350 in 
its antibody solution, and its complementary blocking peptide (Santa Cruz, sc-6416P) 
were mixed at 50:1. Steps described in section 2.4.3 were thereafter followed.    
 
2.7 Cell line analysis 
 
2.7.1 Short Tandem Repeats (STR):  
 
DNA extracted from NOK, Liv37K and PE/CA-PJ15 cell pellets and diluted to a 
concentrations of 5ng/µl. STR was undertaken using GenePrint10® (Promega), and 
analysed to confirm the identity of the cell lines.  
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2.7.2 Mycoplasma testing 
 
A similar aliquot of DNA in section 2.7.1 was allocated for mycoplasma testing. 
Mycoplasma testing was carried out using E-Myco PCR detection kit (CHEMBIO Ltd – 
25235). 
 
2.7.3 Tissue Culture:  
 
The cell lines, PE/CA-PJ15, Liv37K and NOK (normal oral keratinocyte), were 
resurrected from liquid nitrogen store and cultured. Table 2.1 summarises origin of 
the cell lines and culture medium used. Incubation was at 37®C and 5.0% Carbon 
dioxide. Monolayer of cells at approximately 85% confluence were harvested by 
trypsinisation to recover cells and reseeded into new flasks according to desired 
confluence. 
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Table 2.1 Summary of established cell lines used for cell line analysis. Liv37K and 
PE/CA-PJ15 are oral cancer cell lines while NOK (normal oral keratinocyte is a non-
cancer cell line used as a control cell line in this study. The Liv37k cell line has been 
tested at > 40 passages and shown to grow indefinitely. The table includes sources of 
the cell lines, culture medium and the starting passage numbers The cell line Liv37K has the 
capacity to grow ell line Liv37K has the capacity to grow indefinitely (tested at >40 passages 
 
 
 
 
2.7.4 Harvest of cell pellets:  
 
Cell pellets for onward protein extraction and western blot analysis were prepared 
by scraping cell monolayers into 10ml PBS, followed by centrifugation at 1330g for 5 
minutes to recover cell pellets. These were stored at -80®C prior to protein 
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extraction. Protein extraction, quantification and western blotting were carried out 
using the same protocol as for tissue. 
 
 
2.8 Proliferation assays:  
 
Crystal violet assay and MTT (MethylThiazolTetrazolin) assay were used to estimate 
cell proliferation and to establish a G418 kill / survival curve for the various cell lines 
prior to transfection for over-expression experiments.  
 
2.8.1 Seeding of cells and G418 selection:  
 
Cells were seeded in a 12 well plate to achieve approximately 50% confluence after 
24 hours (5K for PE/CA-PJ15, 10K per well for NOK and Liv37K). After 24 hours, G418 
solution (Calbiochem, Cat: 345810-1GM) was added to give serial concentrations of 
0, 200, 400, 800 and 1000µg/ml in culture medium for NOK and Liv37K, and, 0, 500, 
1000, 1500 and 2000µg/ml for PE/CA-PJ15. All assays were undertaken in triplicate. 
G418 solution was renewed 24 hourly, and cell survival was estimated every 24 hours 
for 5 days as follows: 
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2.8.2 Staining with crystal violet solution: 
 
Cells were washed briefly with PBS and air-dried for 5 minutes. Then stained with 
crystal violet (Sigma) solution (0.05% in PBS), incubating at room temperature for 30 
minutes. Crystal violet solution was withdrawn and cells washed under running tap 
water a few minutes, and left to air-dry overnight at room temperature. The following 
day, 200µl of 10% acetic acid was added to solubilise the crystal violet and 100µl 
transferred into 96 well plates. Absorbance was read at 570nm using a Spectramax-
Plus284 absorbance microplate reader (Molecular Devices), against a 10% acetic acid 
blank. 
 
 
2.8.3 Staining with MTT solution 
 
Cells were washed briefly with PBS. Then incubated in fresh culture medium 
containing 0.5mg/ml MTT solution at 37ᵒC for 2 hours. MTT solution was withdrawn 
and the cells fixed with 500μl of chilled 3.7% formalin (pH 7.4) for exactly 12 minutes 
at room temperature. Formalin was withdrawn, and MTT solubilised with 400μl of 
DMSO. 100µl of the resultant solution was transferred to fresh plates (96 well) and 
absorbance read at 570nm using a microplate reader against a DMSO blank. 
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2.8.4  Survival / Kill curve:  
 
Absorbance values were plotted against time (in days), and the minimum 
concentration of G418 sufficient to complete cell death (shown graphically by a 
decline in surviving cell population) was identified for each cell line. 
 
2.9 Over-expression of iRhom2: 
 
2.9.1 Plasmid:  
 
Isoform 2 of the RHBDF2 gene was previously synthesised and cloned (Epoch Life 
Sciences Inc., Fort Bend County, Texas) into the multiple cloning site of-5.3kb 
pIRESneo vector (Cat No. 6060-1), (Figure 2.2). It contains a P (CMVIE) promoter 
region to allow expression in mammalian cells at 232-820, with its multiple cloning 
site occupying 909-974. Its synthetic intron (IVS) which helps with stability of mRNA 
is at 974-1269, while the internal ribosomal entry site (IRES) of the 
encephalomyocarditis virus (ECMV) occupies 1295-1880 to permit translation of two 
open reading frames from one mRNA. Next is the neomycin phosphotransferase gene 
(NPT II) at 1906-2709 to aid in the selection of transfected cells, a fragment containing 
the bovine growth hormone poly A signal at 2710-2998, and the ampicillin resistance 
gene at 5117-4257327.  
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Figure 2.2 Restriction map of the pIRESneo vector: 
Restriction map of the pIRESneo vector. Isoform 2 of RHBDF2 was cloned into the 
EcoR1 site of the multiple cloning site327. 
 
 
2.9.2 DNA extraction:  
 
Bacterial stocks were streaked onto selective media (50mg/ml Ampicillin) and 
individual colonies used to inoculate 5ml LB broth which were cultured for 7 hours at 
37ᴼC with shaking. 
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200µl of the resultant bacteria culture was further incubated overnight in 200ml of 
LB broth with same ampicillin concentration. Both rounds of incubation were 
undertaken at 225rpm / 37ᴼC. 
Plasmid DNA was extracted using a QIAGEN plasmid midi kit, following the 
manufacturer`s protocol. Extracted DNA was quantified using a Nanodrop100 
machine (Thermo Scientific) and stored at -20®C prior to use.  
Gel electrophoresis was carried out on 1% agarose gels with 10µl of Cyto 60 added 
to the gels for direct visualisation using a Licor Odyssey scanner. A restriction digest 
was previously carried out to confirm DNA was as expected. 
 
 
2.9.3 Production of over-expressing clones   
 
Cells were trypsinised, centrifuged at 1330g speed to completely eliminate trypsin, 
reconstituted in culture medium and seeded into T25 flasks thus: 
 NOK-50K cells per flask 
 Liv37K-50K cells per flask 
 PE/CA-P515-30K cells per flask 
In order to achieve approximately 80% confluence after 24 hours. For each flask, a 
DNA solution was prepared containing: 
 340μl of OptiMem (Gibco) 
 30μl of plasmid DNA (at 200mg/ml) 
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 6μl of Lipofectamin Plus (Invitrogen) 
and a Lipofectamin LX solution containing  
 300μl of OptiMem (Gibco) 
 24μl of Lipofectamin LX (Invitrogen) 
These solutions were mixed and allowed to incubate for 5 minutes at room 
temperature before adding 600ml of the combined solution to the culture medium 
in each T25 flask 
The cells were incubated and the medium was left unchanged for: 
 72 hours in NOK flasks 
 72 hours in Liv37K-flasks 
 48 hours in PE/CA-PJ15 flasks 
The incubation time for PE/CA/PJ15 was less as they were less tolerant to the 
transfection reagent. Thereafter, transfection medium was withdrawn, and replaced 
with fresh culture medium that was changed daily to allow surviving cells to recover 
from the trauma of transfection  
After 48 hours, surviving cells were trypsinised to separate them from dead cells and 
reseeded unto new T75 flasks with 10ml of fresh culture medium introduced. 
The cells were allowed to grow to about 60% confluence and then G418 added for 
clone selection thus: 
 NOK-100mg/ml of G418 
 Liv37K-100mg/ml of G418 
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 PE/CA-PJ15-1200mg/ml of G418 
G418 solution was renewed every 48 hours for 10 days and then selection stopped 
to allow surviving cells recover. Cells were passaged after a further 2 days into 3 new 
T75 flasks, to create cells from which pellets would be derived for expression analysis 
by qPCR and western blotting. 
 
2.9.4 Selection of single colonies:  
 
Transfected cells were seeded at low density in 24 well plates with the aim of 
achieving small singular discrete colonies in some of the wells. Culture medium was 
renewed after 24 hours and wells checked for those with single colonies. Such wells 
were marked, G418 selection carried out and cells were allowed to grow to about 
80% confluence before trypsinisation and seeding into T25 flasks to grow on. 
Resultant clones were checked for iRhom2 overexpression through western blotting 
and one clone selected for proliferation / migration assays.   
 
 
2.10 shRNA knock-down:  
 
Mission®shRNA plasmid bacterial glycerol stock (SIGMA – 09051604MN) and 
Mission®pLKO.1-puro BZM shRNA control plasmid DNA (SIGMA-SHC008-
04021321MN), plus Mission®pLKO.1-puro Empty Vector Control Plasmid DNA 
(SIGMA-SHC001-04101509MN) were used. Bacteria culture, plasmid DNA extraction, 
 108 
 
transfection of cell lines and culture followed the same protocol as for production of 
over-expression clones described in section 2.6 
In lieu of G418, 2µl of puromycin (5mg/ml) in 10ml of culture medium was used. 
Treatment was for 48 hours, after which it was withdrawn and replaced with fresh 
culture medium. Medium change was carried out every 24 hours for 3 days, and the 
level of knockdown was evaluated using western blotting. Individual clones were 
isolated following the same protocol outlined in section 2.8, with the use of 
puromycin in place of G418. Western blotting was used to evaluate the resultant 
clones and one was picked for proliferation and migration studies. For the control 
knockdowns using control plasmid DNA, individual clones were not selected, rather, 
the resultant population was utilised for western blot verification   
 
2.10.1 RNA expression analysis:  
 
RNA was extracted from NOK, LIV37K and PE/CA-PJ15 cell pellets using QIAGEN 
RNeasy purification mini kit (Cat No. 74104), following the manufacturer`s protocol. 
RNA concentration was determined using the nanodrop machine (model and 
manufacturer).  
500ng of total RNA was reverse transcribed in a volume of 20μl using High capacity 
cDNA reverse transcription kit (Applied Biosystems – 4368814) to obtain cDNA.  
8μl of cDNA was amplified using FAM labelled RHBDF2 Taqman primer/probe set 
(Assay ID - Hs 01079432 – Applied Biosystems), assayed on an Applied Biosystems 
7500 Fast Real- time PCR system. Data was subsequently analysed on the 7500 
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Software v2.3 (Applied Biosystems). Final values for RNA expression were in relative 
quantification values (RQ), calculated thus: R=2^(-(ΔCtsample-ΔCtcal)), with the mRNA 
expression of the wild type of each cell line used as a calibrator for each set. Assays 
were in duplicates, with the mean value used for analysis. Β-Actin was used as the 
endogenous control. 
 
 
2.11 Proliferation assay:  
 
Wild-type, shRNA knock-down and overexpressing variants of NOK, Liv37K and 
PE/CA-PJ15 cell lines were all trypsinised and seeded in individual 6 well plates and 
in triplicates. 10k per well for NOK and Liv37K, while PE/CA-PJ15 were seeded at 5k 
cells per well. Culture medium was changed every 24 hours for 5 days and cells were 
harvested daily for crystal violet analysis as described in section 2.4. 
 
 
2.12 Scratch assay:  
 
Cells were trypsinised and seeded into removable chambers (Ibidi). Experiments 
were done in triplicates with the removable chambers placed at the centre of wells 
of 6 well plates. All the NOK and Liv37K cell line variants were seeded at 25k cells per 
chamber, with PE/CA-PJ15 cells seeded at 10k cells per chamber. Medium was 
augmented after 24 hours and cells allowed to replicate a further 24 hours to 
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confluence of about 85%. The culture medium was withdrawn, followed by three 
rounds of washes with PBS, and the removable inserts were gently withdrawn before 
introduction of fresh culture medium. The plates were transferred to a 5% Carbon 
dioxide / 37ᴼC chamber attached to a microscope (Micro-manager 4 – Nitcon Eclipse 
TE300) for image capture at ten minutes intervals for 30 hours. Gap closure images 
were analysed on Image J and T-Scratch.  
 
 
2.13 Statistical analysis:  
 
Protein expression data from tumour and normal tissue was analysed using box plot 
analysis and paired sample T test (SPSS statistics, version 24). An Ogive (Cumulative 
frequency curve) was used to establish categorical groupings. Chi square and the 
Kaplan Meier survival test were used to analyse associations between tissue 
expression and clinicopathological features including, survival, recurrence, tumour 
stage, extracapsular spread, and tumour differentiation.  
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3 Baseline expression of iRhom2 and ADAM17 in oral cancer and oral 
non-cancerous tissues 
 
 
3.1 Introduction and aims 
 
It is being proposed that the rhomboid protein, iRhom2 may be implicated in a 
number of cancer types, including head and neck cancer. Its discovery was in 
connection with its role in EGFR activation and signalling283, with EGFR signalling 
already widely implicated in cancer pathogenesis171. More recently, newer roles such 
as the trafficking and shedding of the metalloprotease, ADAM17 have been 
identified. Experiments have implicated deregulation of both proteins, iRhom2 and 
ADAM17 in carcinogenesis219,325. There is the current hypothesis that, increased 
expression of iRhom2 in cancer cells may be involved in the pathogenesis of cancer, 
and possibly promoting metastasis. The aim of this chapter is to estimate and 
compare the levels of expression of the two proteins, iRhom2 and ADAM17; in head 
and neck cancer tissues and adjacent normal or non-cancerous tissues, using western 
blotting and immunohistochemical of previously assembled TMAs containing archival 
tissue from 112 HNSCC patients326. Expression of these proteins in tumour and 
normal tissues was also correlated with a number of clinicopathological features that 
reflect tumour stage and aggression.  
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3.2 Results 
 
3.2.1 Assessment of tumour content in tissues: 
 
The cohort of 137 tissue samples (99 tumour and 38 paired normal tissues) selected 
for this experiment, were independently validated (by a pathologist) for tumour and 
normal tissue content by H & E staining of two 5μm sections from each sample to 
verify the tumour load of each sample (Figure 3.1). A cut-off of 60% tumour load was 
used for tumour samples to be included in this study, while > 5% of tumour cell 
population was unacceptable for normal samples. Using this criteria, a total of 68 
tumours and 27 normal tissue specimens were used in this study (Appendix 3). 
 
 
3.2.2 Blocking peptide / Competition studies 
 
Initial western blot analysis probing for both iRhom2 and ADAM17 displayed multiple 
bands at the proposed molecular weights suggested by suppliers of the primary 
antibodies used, suspecting a lack of specificity. It was therefore necessary to identify 
bands that represented the iRhom2 and ADAM17 proteins.  
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Figure 3.1 : H & E (Haematoxylin and Eosin) staining of tissue samples:  
Two examples of H & E stained slides at X 4 magnification, to determine approximate 
amount of tumour cell content. Top panel shows sample with approximately 75% 
tumour content. There is also the presence of inflammatory cells. Bottom panel 
shows a slide with about 50% tumour cell content, with the other portion taken over 
by inflammatory cells and cancer associated fibroblasts.  
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Blocking peptide/competition studies were employed for this identification / 
confirmation step. iRhom2 blocking peptide experiments removed 2 proteins of 
molecular weights between 76KDa and 102KDa, and reduced the intensity of a 
smaller protein band between 32KDa and 46KDa (Figure 3.2). The two uppermost 
bands (close to 100KDa), are the isoforms of iRhom2, and the third band of interest 
about midway between 32KDa and 46KDa might be a cleaved product. Additional 
bands between 46KDa and 58KDa become more prominent on blocking iRhom2 
antibody (Figure 3.2), indicating the presence of non-specific bands. In ADAM17 
peptide blocking, three protein bands between 95KDa and 130KDa were removed 
when the C-terminal ADAM17 antibody was blocked (Figure 3.3), and prominent 
bands at approximately 70KDa disappearing significantly. Therefore, bands at 
approximately 100KDa were taken as indicative of iRhom2, those between 95KDa and 
130KDa for the immature form of ADAM17, and at about 70KDa for the mature form 
of ADAM17.     
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Figure 3.2 Blocking peptide / competition studies for iRhom2 
Blocking peptide / Competition studies for iRhom2 using the cell line PE/CA-PJ15. Left 
panel: - iRhom2 expression in the presence of iRhom2 blocking peptide. Right panel: 
- iRhom2 expression pattern in the absence of iRhom2 blocking peptide. Three bands 
of interest are removed by the blocking peptide. The three bands are visible on the 
right, but not the left membrane (panel). The three bands include two, just above and 
just below the 100 KDa mark, and a prominent band between the 46KDa and 32KDa 
marks. The top two are two isoforms (1 and 2) of iRhom2 protein, while the lightest 
is thought to be an important degradation product of iRhom2. 
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.  
Figure 3.3 Blocking peptide / competition studies for ADAM17 
Blocking peptide / Competition studies for ADAM17 using the cell line PE/CA-PJ15. 
Left panel: - ADAM17 expression in the presence of ADAM17 blocking peptide. Right 
panel: - ADAM17 expression pattern in the absence of ADAM17 blocking peptide. 
Four bands of interest have their intensities considerably reduced following the 
addition of the ADAM17 blocking peptide. Three of these bands are visible between 
the 150KDa and 95KDa marks, with the fourth just above the 72KDa mark. The three 
higher bands represent the immature forms of ADAM17, while the lowest, just above 
the 72KDa mark represents the mature form of the protein The C-terminal ADAM17 
antibody (Santa Cruz, sc-6416) was utilised here to target both the immature and 
mature forms of the protein.    
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3.2.3  iRhom2 expression in tumour and adjacent normal tissues:  
 
Variable levels of iRhom2 expression were demonstrated in the tissue samples 
(Figure 3.4). Densitometry was used for quantitative assessment of the levels of 
expression and the data correlated for loading, then normalised against the over-
expressing TE3 positive control that was run on every gel (see section 2.5 of materials 
and methods, and Figure 2.1). A status of High, Moderate and “no expression” were 
ascribed based on a cut-off of 20 arbitrary units determined from the 75th percentile 
/ upper quartile of the cumulative frequency curve of the data (Figure 3.5 and Figure 
3.6).    
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Figure 3.4 Examples of western blot for iRhom2 expression in tissues: 
Upper and lower panels (membranes) show varying levels of iRhom2 expression in 
tumour and normal tissues. TE3 cells over-expressing iRhom2 were used as positive 
control in the first lanes (from left) on both panels. The position of iRhom2 isoforms 
is indicated, with β-Actin loading controls shown below the iRhom2 gels. Lane 2 from 
right, on the Top panel is a tumour sample, a good representation of iRhom2 over-
expression. Lane 1 from right on the same membrane is a normal sample with no 
detectable iRhom2 expression, while lane 4 from right shows moderate expression.  
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Figure 3.5 Determination of cut-off from Ogive. 
Cumulative frequency curve generated using iRhom2 densitometry values for tumour 
and paired normal samples. A cut-off point of 20 arbitrary units was derived from the 
Ogive to correspond with expression at the upper quartile (75th percentile). 
Densitometry values above this cut off were taken to represent over-expression while 
those below it will represent moderate or no expression. 
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Figure 3.6 Distribution of levels of iRhom2 expression: 
Based on the cut-off point of 20 arbitrary units derived from the Ogive, and a second 
cut-off of 11 arbitrary units, obtained from the formula, mean + 2 S.D (representing 
densitometry values >95% average value for normal tissues), expression levels were 
graded. Dark orange - > cut off, Light orange - ≤ cut off, and White = zero arbitrary 
unit, and the table shows a summary of the distribution of levels of iRhom2 
expression based on both cut-off points. Irrespective of the cut-off used, more 
tumour tissues over-express iRhom2; than normal samples. With a cut-off of 11 for 
instance, 40% of tumour samples were shown to over-express iRhom2, compared to 
7% for normal samples. 
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Figure 3.7 Summary of the levels of iRhom2 expression: 
A boxplot showing a summary of the levels of iRhom2 expression in tumour and 
normal samples. Two outliers are conspicuous within the cohort of normal tissues, 
and these are thought to be normal tissues that might either have significant but yet 
undetected tumour cell infiltration, or those originating from skin or tissues rich in 
myeloid cells, which are known to be strongly positive for iRhom2328. 
 
 
A second approach to establish a cut-off was also used, in which overexpression in 
tumour tissues was ascribed to densitometry values >95% average value for normal 
tissues (mean + 2 S.D). Using this method, the cut off was set at a densitometry value 
of 11 [2.26 + 2(9.176)], giving the number of tumour samples with the “highly 
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expressing” of 27/68 (40%), compared with 19/68 (28%), when using the upper 
quartile method (Figure 3.6).   
 
 
3.2.4   ADAM17 expression in tumour and adjacent normal tissues:  
 
Probing for both the mature and immature forms of ADAM17 in the cohort of tumour 
and normal samples (using the C-terminal ADAM17 antibody) also produced evidence 
of variable levels of expression (Figure 3.8). The immature form of ADAM17, with an 
expected band about 110KDa, was observed in 63/68 (93%) of the tumour samples; 
and 14/27 (52%) of the normal samples. However, probing for the mature form of 
the protein, expected to be around 75KDa, demonstrated expression in 38/68 (56%) 
of tumour samples and 7/27 (26%) of normal samples. The activated (mature) form 
is expected to be concentrated at the cell membrane but likely in relative minute 
amount compared to the intracellular pool of immature ADAM17. Though yet 
unverified, we suspect that the concentration of mature ADAM17 at the membrane 
(where shedding activities are meant to be concentrated) may be a direct reflection 
of a number of factors including the level of abundance of its immature cytoplasmic 
pool. 
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Figure 3.8 Expression of ADAM17 in tissues: 
Mature ADAM17 of about 75KDa is shown to be expressed in varying levels by 
tumour and normal tissue samples. The same TE3 cell line used for iRhom2 
expression is maintained as positive control.  From left, lanes 2, 4, 6 and 7 are 
examples of ADAM17 over-expression, with lanes 3, 5 and 8 showing normal 
ADAM17 expression. β-Actin loading controls have been shown below the ADAM17 
gel. 
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3.2.5  Correlation of iRhom2 and ADAM17 expression with clinicopathological data.  
 
Having established an increased iRhom2 expression pattern in tumour samples 
compared to paired normals, an attempt was made to establish possible correlations 
between levels of protein expression and clinicopathological features that may 
directly or indirectly serve as indices for malignancy. iRhom2 and ADAM17 expression 
in tumour samples was compared with the following features: tumour site, size, 
extra-capsular spread, histological differentiation and survival. Only oral cancer cases 
were included in these analyses. Oropharyngeal cases which had been included in the 
western blot experiments were excluded. There was no significant correlation 
between iRhom2 expression and any of the clinicopathological features except for 
survival. ADAM17 expression did not correlate with any clinicopathological features. 
 
3.2.5.1  iRhom2 expression and survival.  
 
For this analysis, survival was taken as the time from the date of surgery to death (or 
date last seen, for patients who are still alive) in months. iRhom2 expression was 
categorised as over-expressed as defined by the two densitometry cut-off values 
derived earlier, 19.9 and 11, and Kaplan Meier curves were constructed. With a 
densitometry cut-off of 11, iRhom2 expression was shown to correlate negatively 
with survival (p=0.000 for the higher cut-off of 19 and p=0.007 for 11 cut-off) (Figure 
3.9).  
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Figure 3.9 Kaplan Meier survival analysis: 
Kaplan Meier survival analysis of 44 clinical samples in relation to levels of iRhom2 
expression. Top panel: cumulative survival with cut-off set at 11 arbitrary 
densitometric units. Bottom panel: cumulative survival with cut-off set at 19.9 
arbitrary densitometric units. 
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3.2.6 Intracellular localisation of iRhom2 and ADAM17 by IHC of TMAs  
 
A set of TMA cores previously assembled were scored in an attempt to determine the 
location and degree of expression among different cell types in intact oral cancer 
tumour tissues. Unexpectedly, all of the iRhom2 stained cores were either negative 
or weak. This may be due to relatively small amounts of the protein iRhom2 or the 
need for improved optimisation of the protocol. For instance, it is a possibility the 
antibody used is not suitable for IHC on FFPE (formalin fixed paraffin embedded) 
sections, considering some antigens are not detectable after FFPE treatment. This is 
while assuming the control sections may not have been stained adequately. 
 
ADAM17 expression was evaluated on the TMAs. The staining was however observed 
to be likely non-specific with regards to discriminating between the mature and 
immature forms of ADAM17. ADAM17 is thought to be relatively abundant in its pro-
form in the cytoplasm and in relatively smaller amounts as active or matured 
ADAM17 at the cell membrane234. It is this active form at the cell membrane that is 
thought to carry out shedding activities on other proteins towards their subsequent 
activation219. It is therefore important to be able to differentiate between the two 
forms as the former is likely to only be a store and is non-functional. The antibody 
used was intended to primarily target the active form of the protein at the cell 
membrane, but TMA cores showed mainly abundant cytoplasmic staining and only a 
handful of weak membranous staining. This shows that expression of functional 
ADAM17 protein was infrequent. It was also noted in some of the cores that the 
strength of staining varied from one part of the cytoplasm to the other. One 
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explanation could be that, since activation or maturation of ADAM17 takes place in 
the Golgi apparatus, and the mature molecule is then transported to the cell 
membrane, some of this active or mature form of the protein can be observed in the 
cytoplasm enroute to the cell membrane. Despite these reservations, it has been 
demonstrated for other cancer associated proteins E.g. FANCD2, that altered cellular 
localisation of proteins may be associated with clinical parameters329. However, no 
correlations between ADAM17 staining and clinicopathological features were 
observed in this cohort. The bioavailability of the protein may be reduced at the cell, 
such that detecting it via routine protocols becomes a challenge. 
 
 
3.2.7 TMA (tissue microarray) scores and analysis. 
 
In order to determine the location of increased iRhom2 and ADAM17 expression in 
intact tumour tissue, TMAs containing triplicate cores from tumour and normal 
adjacent tissue from 112 patients326 were probed for iRhom2 and ADAM17. ADAM17 
expression ranged from “no staining” to “strong staining” (Figure 3.10).  
 
 129 
 
 
 
Figure 3.10 ADAM17 staining on tumour cores: 
Figures showing different levels of ADAM17 staining on tumour cores. Top-left panel 
shows a core with weak (+), Top-right panel demonstrates moderately staining 
tumour and the Bottom panel illustrates strongly stained tumour. Tumour areas are 
illustrated by arrow heads.  
 
 
A number of the cores demonstrated more than one level of intensity across the 
tissue, in which case the most prevalent staining pattern was taken as representative 
degree of staining. Apart from a few cases, most of the triplicates were not far from 
each other in terms of staining intensities. For each triplicate set, the most 
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representative score (i.e. present in 2 or more cores) was adopted as a consensus 
score (Table 3.1). Following the removal of data from non-oral cancer cases, a smaller 
cohort of 88 patient samples was analysed.  
 
Table 3.1 Examples of TMA triplicate scores and the consensus scores arrived at.  
 
 
 
Very few wholly negative or weakly staining cores were observed for ADAM17 (Table 
3.2), so data from “negative” and “weak” were consolidated into a single category. 
Unexpectedly, the staining for iRhom2 was almost exclusively negative and were not 
analysed further.  
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Table 3.2 The distribution of ADAM17 consensus staining in TMAs 
 
 
 
3.2.7.1  ADAM17 TMA expression and clinicopathological features. 
 
Some of the less common sites of oral cancer were represented rarely in this 
sample set, so the primary oral tumour sites were regrouped into 3 categories, 
tongue, floor-of-mouth (FOM) and others. The “Others” category included those in 
the retromolar, lower and upper alveolus, lower alveolar ridge, and hard palate 
region. There was no significant correlation between ADAM17 expression and 
primary tumour site. 
ADAM17 expression was also compared with other clinicopathological features, but 
did not show any significant correlation between levels of expression and survival, 
ECS (extracapsular spread), tumour size, nodal involvement, and recurrence.     
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3.3 Summary and discussion of findings 
 
3.3.1  Assessment of tumour content of frozen specimens 
 
A total of 137 clinical samples in form of tissues obtained from surgery and snap 
frozen were screened for inclusion in this study. Analysis of H & E stained sections 
was performed and results showed 28/137 were not suitable for inclusion in the final 
cohort. Apart from few which were too small in size for these experiments 
(particularly normal tissues, n=11), most of those excluded was on the basis of 
containing too little cancer cells to be confident that the data obtained was from 
tumour cells. Adopting 28/137 as a working ratio would mean that, if any new study 
is intended to analyse a particular sample size, then this ratio may be applied to 
increase overall number of tissues recruited in order to allow for tissues that may be 
discarded as inadequate. 
ADAM17 expression was evaluated on the TMAs. The staining was however observed 
to be likely non-specific with regards to discriminating between the mature and 
immature forms of ADAM17. ADAM17 is thought to be relatively abundant in its pro-
form in the cytoplasm and in relatively smaller amounts as active or matured 
ADAM17 at the cell membrane234. It is this active form at the cell membrane that is 
thought to carry out shedding activities on other proteins towards their subsequent 
activation219. It is therefore important to be able to differentiate between the two 
forms as the former is likely to only be a store and is non-functional. The antibody 
used was intended to primarily target the active form of the protein at the cell 
membrane, but TMA cores showed mainly abundant cytoplasmic staining and only a 
handful of weak membranous staining. This shows that expression of functional 
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ADAM17 protein was infrequent. It was also noted in some of the cores that the 
strength of staining varied from one part of the cytoplasm to the other. One 
explanation could be that, since activation or maturation of ADAM17 takes place in 
the Golgi apparatus, and the mature molecule is then transported to the cell 
membrane, some of this active or mature form of the protein can be observed in the 
cytoplasm enroute to the cell membrane. Despite these reservations, it has been 
demonstrated for other cancer associated proteins E.g. FANCD2, that altered cellular 
localisation of proteins may be associated with clinical parameters329. However, no 
correlations between ADAM17 staining and clinicopathological features were 
observed in this cohort. The bioavailability of the protein may be reduced at the cell, 
such that detecting it via routine protocols becomes a challenge. 
 
 
3.3.2 Total protein expression of iRhom2 in oral cancer. 
 
On western blot, variable expression of the iRhom2 protein was observed. This was 
expected, having been shown previously that some tissues probably did not express 
the protein. In my experiments, the frequency of any iRhom2 expression was higher 
in tumour samples with 45/68 (66%), than in normal sample 6/27 (22%) (p<0.05). 
Furthermore, the level of expression was generally greater in tumour tissues when 
either a stringent cut-off of 19.9 arbitrary densitometry units (top quartile of 
expression), or a “normal” cut-off of 11 units (mean of normal tissues + 2 SD) was set 
as the limit for overexpression. Analysis was based on expression of isoforms 2. The 
increased expression of iRhom2 in tumour tissues may be in direct response to an 
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increased demand for availability of mature ADAM17 at the cell membrane. This 
could be the case, with a number of studies already implicating ADAM17 in 
tumorigenesis246,279. It may also be that the effect is in iRhom2 expression (either 
upregulation or increased stability due to activating mutations)330, resulting in 
increased availability of ADAM17 on the cell surface. This in turn activates, for 
example, the EGF or notch pathways. Tumour samples in which iRhom2 expression 
could not be demonstrated may therefore be those without inherent ability to 
express the protein, or where a different pathway is available to sustain tumour 
growth. 
 
                  
3.3.3 Total protein expression of ADAM17 in oral cancer 
 
ADAM17 expression levels were variable in the tissues analysed. Generally, tumour 
tissues were found to have a higher level of ADAM17 expression, considering either 
expression of the immature form or the mature form. This is in keeping with available 
data suggestive of an oncogenic role for ADAM17, including oral cancer cases, where 
increased expression has been implicated in tumorigenesis246. We hypothesised that 
expression of the mature form might be in direct response to signals for increased 
shedding activities, therefore our correlation with clinicopathological features was 
based on the mature form. Also, iRhom2 protein expression correlated with both 
mature and immature ADAM17 expression (p<0.001). 
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3.3.4 iRhom2 expression correlates with patient survival 
 
iRhom2 expression levels in tumour samples correlated with survival, but not with 
other clinicopathological features examined. However, ADAM17 expression did not 
correlate with survival. 
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4 CHAPTER 4: Functional changes in head & neck cell lines 
following up/down-regulation of iRhom2 
 
 
 
4.1  Introduction and aims:  
 
The deregulation of iRhom2 and ADAM17 have been implicated in the development 
of a number of cancers331-333, with my data now eliciting the inclusion of oral 
carcinomas to the list. There is the hypothesis that, increased expression of iRhom2 
in cancer cells may be involved in the pathogenesis of cancer, and possibly supporting 
increased metastasis. Data from the previous chapter on tissue analysis shows that 
increased iRhom2 in oral cancer tumour tissues is associated with poor prognosis and 
may thus be a marker of “aggression”. There was however no observable correlation 
between the levels of iRhom2 expression and other markers of aggression such as 
extra-capsular spread (ECS). The aim of this section is to investigate a possible role 
for iRhom2 in tumour aggression in head and neck cancer cell lines in which iRhom2 
has been up/down-regulated. 
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4.2 Results:    
 
4.2.1 Profiling of cell lines:  
 
Baseline expression of iRhom2 and ADAM17 by a cohort of head and neck cell lines 
was determined by western blot (Figure 4.1 and Figure 4.2). The cell lines; PE/CA-
PJ15 and PE/CA-PJ14 showed relatively high levels of iRhom2 expression, while low 
expression was observed in NOK, Liv7, Liv72 and Liv22K, with a rather intermediate 
level of expression in Liv37K (Figure 4.1). All the cell lines analysed expressed high 
levels of the immature form of ADAM17 (Figure 4.2), with observed differences in 
the banding patterns, likely reflecting different post-translational modifications in 
different cell lines. For instance, the two PE/CA cell lines (and to some degree Liv37K) 
have an additional, strong band at approximately 100KDa. PE/CA-PJ15 and PE/CA-
PJ41 also showed a prominent band representing the mature form of ADAM17 at 
approximately 76KDa, while a small fragment, likely the cleaved N-terminal region 
(not confirmed) was only detected in PE/CA-PJ15 (Appendix 3). The mature form of 
the protein was present at low levels in Liv37K, Liv22K, Liv72K, Liv7K and NOK. Two 
head and neck cancer cell lines, PE/CA-PJ15 and Liv37k, and the normal oral 
keratinocyte cell line, NOK, were selected for functional studies based on their 
expression pattern (Figure 4.3) 
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Figure 4.1 Profiling of iRhom2 expression: 
Profiling of iRhom2 baseline expression in six oral cancer cell lines and normal oral 
keratinocytes (NOK) to determine suitable options for cell line analysis– “iRhom2 
arrow” points at the target band (iRhom2 Isoform 2). The prominent band just above 
it is the iRhom2 Isoform 1, which is not the target band in this experiment. Cell lines 
were probed in duplicates with bold letterings representing proteins from a separate 
flask. The PE/CA-PJ cell lines (PJ15 and PJ41) are shown to have significant baseline 
levels of iRhom2, unlike the other cell lines. 
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Figure 4.2 Profiling of ADAM17 expression: 
Profiling of ADAM17 expression in six oral cancer cell lines and normal oral 
keratinocytes (NOK). Arrow heads point at bands representing the mature and 
immature forms of the protein. Apart from the Liv22 and Liv7 cells with moderate 
levels of immature ADAM17, all the other cell lines appear to have a high level of 
immature ADAM17 (seen between the 100KDa and 135KDa marks). The mature form 
of the protein (at about the 75KDa point) could only be demonstrated in the PE/CA-
PJ cell lines (PJ15 and PJ41).  
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Figure 4.3 iRhom2 and ADAM17 expression pattern: 
ADAM17 and iRhom2 expression patterns are represented as colour codes where, the 
darker the colour shade, the higher the relative level of expression of the protein 
(based on cut-offs from the constructed ogive). The mature form of ADAM17 protein 
is demonstrated in the PE/CA cell lines (PJ15 and PJ41), with all the cell lines shown to 
express its immature form. iRhom2 is shown to be highly expressed in the PE/CA cell 
lines, compared to moderate expression levels in the Liv37k cells. 
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4.2.2 Generation of G418 kill / survival curves:  
 
Kill / survival curves were generated for PE/CA-PJ15, Liv37K and NOK in the presence 
of G418. Both Crystal violet and MTT assays were utilised to quantify total DNA and 
mitochondria activity respectively, with the assay continuing for up to 5 days. It was 
important to use both assays because this will not only produce a cell count, but those 
of viable cells.  For NOK and Liv37K, a concentration of 200μg/μl of G418 was 
observed to be sufficient to kill cells within 5 days, while a concentration of 2000μg/μl 
was necessary for PE/CA-PJ15. For the eventual killing of untransfected cells, kill 
doses of 100μg/μl and 1500μg/μl were used respectively.  
 
4.2.3 iRhom2 over-expression in NOK, Liv37K and PE/CA-PJ15 cells.  
 
Transfection of PE/CA-PJ15, Liv37k and NOK cell lines with the iRhom2 
overexpressing plasmid, pIRESneo, produced protein overexpression in all three cell 
lines. Single colonies were cultured for each cell line and three to four different 
colonies were analysed for the most efficient transfection in terms of level of iRhom2 
over-expression (Figure 4.6, 4.7 and 4.8). The highest level of overexpression was 
demonstrated by PE/CA-PJ15 cells (Figure 4.5). An additional prominent band 
(50KDa) was consistently observed in all of the overexpressing variants, and may 
represent a degradation product. RNA over-expression was also observed (Figure 
4.4).  
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Figure 4.4 Relative quantification of RHBDF2 overexpression: 
Relative quantification (RQ) of levels of RHBDF2 overexpression in the over-expressing 
variants of NOK, Liv37K and PE/CA-PJ15 cell lines, compared with the parental cell lines. The 
last image compares the relative level of overexpression among the three cell lines. Values 
represent those obtained from qPCR analysis, carried out in duplicates. 
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Figure 4.5 iRhom2 protein over-expression: 
iRhom2 protein over-expression in NOK, Liv37K and PE/CA-PJ15 cell lines: Top- 
western blot following stable transfection with the iRhom2 isoform 2 overexpressing 
plasmid (pIRESneo). Transfected cells (+/+) are shown to have a higher level of 
expression of the iRhom2 protein compared to their corresponding wild types (WT). 
Bottom- relative quantification of iRhom2 isoform2 protein expression, using 
arbitrary densitometry units. The highest level of iRhom2 expression is shown to 
occur in PE/CA-PJ15, however, the biggest impact of over-expression is demonstrated 
with the Liv37k cells. 
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Figure 4.6 Colony selection for Liv37K: 
iRhom2 protein over-expression in 3 different colonies of Liv37K cells, in comparison 
with the wild-type (WT). Left panel shows the western blot result, while the right 
panel is a bar chart to illustrate the degree of iRhom2 over-expression, using relative 
densitometry values. The bar chart includes percentage error bars. The greatest 
transfection efficiency was demonstrated in Colony 3 and these cells were used 
onward for Liv37K (+/+) variants.  
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Figure 4.7 Colony selection for PE/CA-PJ15 cells: 
iRhom2 protein over-expression in 4 different colonies of PE/CA-PJ15 cells, in 
comparison with the wild-type (WT). Left panel shows the western blot result, while 
the right panel is a bar chart to illustrate the degree of iRhom2 over-expression, using 
relative densitometry values. The bar chart includes percentage error bars. The 
greatest transfection efficiency was demonstrated in Colony 2 and these cells were 
used onward for PE/CA-PJ15 (+/+) variants.  
 
 
 
 147 
 
 
 
Figure 4.8 Colony selection for NOK cells: 
iRhom2 protein over-expression in 3 different colonies of NOK cells, in comparison 
with the wild-type (WT). Left panel shows the western blot result, while the right 
panel is a bar chart to illustrate the degree of iRhom2 over-expression, using relative 
densitometry values. The bar chart includes percentage error bars. The greatest 
transfection efficiency was demonstrated in Colony 3 and these cells were used 
onward for NOK (+/+) variants. 
 
 
4.2.4 shRNA knock-down of RHBDF2.  
 
The previously transfected, over-expressing cell lines, were subsequently subjected 
to shRNA knock-down of the RHBDF2 gene, targeting Isoform 2. Scrambled shRNA 
together with an empty vector were used as controls. Interestingly, iRhom2 
expression was reduced below the levels observed in parental cell lines for both 
PE/CA-PJ15 (Figure 4.9) and NOK (Figure 4.10), using clone A (TRCN0000048685), 25 
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times less in PE/CA-PJ15 and 18 times less in NOK. Knock-down experiments using 
Liv37k cell lines did not yield appreciable knock-down (Figure 4.11). The two shRNA 
clones, A (TRCN0000048685) and B (TRCN0000048687) were utilised, separately and 
in combination, for possible RHBDF2 knock-down in Liv37K, without appreciable 
knock-down effect (Figure 4.12). . 
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Figure 4.9 shRNA knock-down of RHBDF2 in PE/CA-PJ15 cells: 
Western blot (Top panel) and relative quantitation (Bottom panel) following shRNA 
knock-down of RHBDF2 gene in over-expressing PE/CA-PJ15 clones. There is a 
significant knock-down effect following shRNA treatment, with iRhom2 expression 
level falling from around 70 relative densitometry units (over-expressing +/+ clones) 
to below 5 (knock-down -/- clones).  
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Figure 4.10 shRNA knock-down of RHBDF2 in NOK cells: 
Western blot (Top panel) and relative quantitation (Bottom panel) following shRNA 
knock-down of RHBDF2 gene in over-expressing NOK clones. There is a significant 
knock-down effect following shRNA treatment, with iRhom2 expression level 
reducing from around 75 relative densitometry units (over-expressing +/+ clones) to 
below 5 (knock-down -/- clones).  
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Figure 4.11 shRNA knock-down of RHBDF2 in Liv37k: 
Western blot (Top panel) and relative quantitation (Bottom panel) following shRNA 
knock-down of RHBDF2 gene in over-expressing Liv37k clones. The knock-down 
effect is not significant, with the (-/-) cells appearing to have similar levels of iRhom2 
expression to the over-expressing clones (+/+). 
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Figure 4.12 RHBDF2 knock-down using multiple shRNA: 
Western blot following attempted shRNA knock-down of RHBDF2 gene in over-
expressing clones of Liv37K cells. The two shRNA clones, A and B, were used 
separately, and in combination as C to attempt knock-down effect, without success. 
All the knock-down clones (-/-), A, B and C appear to have similar levels of iRhom2 
expression compared to the over-expressing clones (+/+). 
 
 
4.2.5 ADAM17 expression following overexpression and shRNA knock-down of 
RHBDF2 
 
The effect of up/down-regulation of iRhom2 on the expression of ADAM17 was 
investigated with immunoblotting, probing for both forms of ADAM17 (mature and 
immature). Increased expression of the mature form of the protein was clearly 
demonstrated in the over-expressing PE/CA-PJ15 cell lines, with a reduction of 
expression in the shRNA knock-down (Figure 4.13 Top and Bottom panels). However, 
mature ADAM17 expression could not be detected in any clones produced from the 
other two cell lines, NOK and Liv37k (Figure 4.13). Expression of the immature form 
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of ADAM17 was increased in iRhom2 over-expressing cell variants of all three cell 
lines, and reduced in 2/3 of the shRNA knock-down cell lines (Figure 4.13, Top and 
Middle panels). There was increased levels of expression of the immature ADAM17 
with increased iRhom2 expression in both NOK and Liv37K cells, but not in PE/CA-
PJ15 cells, where both overexpressing and knock-down cells expressed the immature 
form at relatively equal / elevated levels.       
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Figure 4.13 ADAM17 expression following upregulation of iRhom2: 
Top panel – Western blot analysis of expression of mature and immature forms of 
ADAM17 following overexpression and shRNA knock-down of RHBDF2 in Liv37K, NOK 
and PE/CA-PJ15 cell lines. Levels of the immature form of the protein appear 
unaltered across the variants of all three cell lines. The mature form of the protein is 
however shown to be markedly increased in the PE/CA-PJ15 (+/+) cells. Middle and 
bottom panels – bar charts to illustrate relative quantification of levels of expression 
of the immature and mature forms of ADAM17 respectively. Error bars demonstrate 
mean plus 2 S.D for 2 replicates. 
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4.2.6 Functional analysis  
 
4.2.6.1 Proliferation 
 
The crystal violet assay was used to assay the rate of proliferation of PE/CA-PJ15, 
Liv37K and NOK cell lines and their overexpressing and shRNA knock-down 
derivatives. This assay suggested that overall growth / proliferation was unaffected 
by the changes in iRhom2 expression (Figure 4.14), except for Liv37k where over-
expression of iRhom2 appeared to slow the proliferation rate. 
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Figure 4.14 proliferation assay: 
Crystal violet proliferation assay on NOK, Liv37K and PE/CA-PJ15 cells and their derivatives: Viable 
cell population, represented by the absorbance, is plotted against time in days. Blue line: parental 
cell line; orange line: shRNA knock-down of over-expressing clone; grey line: over-expressing 
clone. With all three cell lines, there seem to be no obvious added proliferative advantage 
following iRhom2 over-expression. Equally, there seem to be no proliferative setback following 
iRhom2 knock-down, with the slopes similar to each other. 
 
 157 
 
4.2.6.2 Migration:  
 
The wound healing assay (scratch assay) was used to assess changes in rate of 
migration between the wild type NOK, Liv37K and PE/CA-PJ15 cells and their 
derivatives. PJ15 (+/+) cells with up-regulated iRhom2 migrated faster than their wild-
type and knock-down variants with the knock-down clone showing the slowest rate 
of migration (Figure 4.15). Complete wound closure by PJ15 (+/+) occurred after 18 
hours but was not achieved by the wild type or knock-down variants until 32 hours. 
iRhom2 over-expression did not appear to alter the rate of migration of NOK cells 
(Figure 4.16). An increased rate of wound closure was observed for Liv37k 
upregulated cells compared with the parental cell line and the same increased rate 
of wound closure was observed in Liv37K cells which unsuccessfully went through the 
knock-down process (Figure 4.17). Considering the rate of migration (in terms of 
wound closure) between the wild type variants of the two cancer cell lines used, 
PE/CA-PJ15 and LIV37K, the PE/CA-PJ15 cells migrated slower than the LIV37k cells, 
in indirect proportion to their baseline iRhom2 expression. Wild type PE/CA-PJ15 cells 
closed the wound after 32 hours (Figure 4.15), unlike wild type LIV37K cells for which 
the same closure took an average of 17 hours (twice faster), (Figure 4.17). Baseline 
iRhom2 expression levels may therefore not be a direct measure for rate of 
migration. NOK cells migrated fastest. Again, the above observation has its 
limitations, considering the fact that the various cell lines were seeded at different 
confluence. It was not possible to seed cells at the same confluence for the three cell 
lines, considering they have different growth rates. Seeding at the same confluence 
therefore would have resulted to overcrowding for PE/CA-PJ15 where LIV37K and 
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NOK are considered adequate. If the rate of migration is directly and considerably 
influenced by the seeding densities, this will therefore explain the reason for the 
rather overall slower closure rate observed with PE/CA-PJ15, considering they were 
seeded least dense.  Consistent with the two cancer cell lines, PE/CA-PJ15 and LIV37K, 
their upregulated variants migrated at approximately twice the rate compared to 
their wild type. This remarkable increase in rate of migration with increased iRhom2 
expression in cancer cells, is an indication that iRhom2 is involved with cell mobility 
in cancer, but at different rates across cells. 
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Figure 4.15 Migration of PE/CA-PJ15 cell lines: 
Migration of PE/CA-PJ15 cell lines using the scratch assay. Top panel - Freeze 
photography taken at the time points indicated to reflect extent of open 
wound/closed area. Middle & Bottom panels – graphical representations of the 
relative rates of wound closure. Orange line/bar: parental cell line; grey line/bar: 
shRNA knock-down of over-expressing clone; blue line/bar: over-expressing clone. 
Experiments were performed in duplicates, with standard error bars shown. 
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Figure 4.16 Migration of NOK cell lines: Migration of NOK cell lines using the scratch 
assay Top panel - Freeze photography taken at the time points indicated to reflect 
extent of open wound/closed area in NOK cell series. Middle & Bottom panels – 
graphical representations of the relative rates of wound closure among the variants. 
Orange line/bar: parental cell line; grey line/bar: shRNA knock-down of over-
expressing clone; blue line/bar: over-expressing clone. Experiments were performed 
in duplicates, with standard error bars shown. 
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Figure 4.17 Migration of Liv37k cell lines: Migration of Liv37k cell lines using the 
scratch assay Top panel - Freeze photography taken at the time points indicated to 
reflect extent of open wound/closed area in Liv37K cell series. Middle & Bottom 
panels – graphical representations of the relative rates of wound closure among the 
variants. Orange line/bar: parental cell line; grey line/bar: shRNA knock-down of 
over-expressing clone; blue line/bar: over-expressing clone. Experiments were 
performed in duplicates, with standard error bars shown. 
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4.2.6.3 Morphological observations:  
 
Morphological changes were observed between the various strains of PE/CA-PJ15 
cells, with the up-regulated clones, PJ15 (+/+) appearing more spindle shaped 
compared to the WT and KD cells (Figure 4.18). There were no obvious morphological 
differences among the variants of NOK and Liv37k cells. 
 
 
 
Figure 4.18 Morphological changes: Phase contrast images of PE/CA-PJ15 and NOK 
derivatives in culture. The PE/CA-PJ15 (+/+) over-expressing clones appear to be 
more elongated with what appears to be somewhat prominent spindles. A similar 
finding is observed with the NOK (+/+) clones, though their knock-down variants, NOK 
(-/-) also appeared similar to the over-expressing clones.  
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4.3 Summary and discussion of findings 
 
4.3.1 Expression of iRhom2 and ADAM17 in cell lines 
 
The parent cell lines profiled expressed iRhom2 and ADAM17 in varying levels. The 
marked variation in iRhom2 expression was expected, considering the variation in its 
expression by the cohort of clinical tissues used earlier, in addition to suggestions 
that certain cells / tissues may not express the protein334. For ADAM17 expression, 
all the cell lines seem to strongly express the immature form but not the mature form. 
Again, this comes as no surprise, considering the protein has been shown to be 
pooled largely in its immature form, with only a relative mature / active fraction at 
the cell membrane227,228. 
 
 
4.3.2 The effect of iRhom2 upregulation on ADAM17 expression. 
 
Upregulation of iRhom2 was achieved in all three cell lines used, but to varying levels, 
as demonstrated on both western blot and by RT-PCR. The highest level of 
upregulation at the RNA level was observed in the PE/CA-PJ15 cell line (approximately 
350 fold compared with 30-40 fold for Liv37k and NOK, respectively). However, 
relative over-expression at the protein level was greatest in Liv37k (approximately 
150 fold compared with 8-12 fold for PE/CA-PJ15 and NOK, respectively), probably 
due to the fact that they demonstrated the highest baseline expression from the 
profiling carried out initially. Equally, there is the possibility that cells have a 
 164 
 
maximum level of iRhom2 they may accommodate, in which case the increased level 
of RNA may not result in a corresponding protein level for PE/CA-PJ15. There is 
however no evidence to this in the literature. The expression of the immature 
inactive form of ADAM17 was observed to approximately double, compared to the 
parental cell line when iRhom2 protein was upregulated in all cell lines tested. 
However, increased expression of the active form was only demonstrated at 
significant levels in one of the cell lines, PE/CA-PJ15, following upregulation of the 
iRhom2 protein. The increased expression of mature (active) ADAM17 may be due to 
the increased bioavailability of iRhom2 (following its upregulation), proposed to be 
responsible for its intracellular trafficking and subsequent activation. The fact that 
this has not been reflected in the other two cell lines may be because, though likely 
increased, the levels might still be sub-optimal for detection by western blot. The 
increased expression of the immature / inactive form of ADAM17 on the other hand 
may be in response to feedback arising from rapid deployment of ADAM17 for 
trafficking by iRhom2. The difference is however less felt considering the fact that the 
immature store is already considered relatively abundant in the cytoplasm. 
Importantly, using Table 4.2 as a guide, it could be argued that, X 350 upregulation 
of iRhom2 at the RNA level for PE/CA-PJ15 has not produced as much effect as X 40 
for Liv37k, suggestive of the fact that there might be a stronger forward gradient in 
Liv37k due to lower baseline levels of iRhom2 in the parental cells. This means the 
iRhom2 levels even in the over-expressing variants may be nowhere near the optimal 
concentrations, and thus, a higher level of over-expression at both RNA and protein 
levels for Liv37k may eventually lead to a detectable amount of mature ADAM17 
resulting from increased bioavailability of the carrier iRhom2. 
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Table 4.2 Relative upregulation of iRhom2 at both RNA and protein levels in PE/CA-
PJ15 and Liv37k 
       
 
 
4.3.3 shRNA knock-down of RHBDF2 reduces iRhom2 and ADAM17 protein 
expression 
 
The most pronounced level of knock-down was demonstrated in the PE/CA-PJ15 cell 
lines (to approximately 0.05 X the level in the parental cell line; 0.01 X the over-
expressing clone), with NOK cells also being successfully knocked down (0.2 X 
parental and 0.01 X over-expressing clone). However, although clones were antibiotic 
resistant, the Liv37k knock-down did not reduce iRhom2 protein levels. This finding, 
followed the same trend with overexpression, and may therefore be due to general 
ease at transfecting the PE/CA-PJ cell line. In PE/CE-PJ15 cells, following shRNA knock-
down of RHBDF2, the levels of immature ADAM17 protein are not affected, but the 
mature protein levels fall to 0.25 X overexpressing clone; in NOK cells there is a 2 x 
reduction of immature protein levels compared with the overexpressing clone but 
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this is approximately equivalent to the parental levels; As expected, no apparent 
change in Liv37K 
A possible explanation would be that, since the knock-down cells are those which 
were previously overexpressing iRhom2, there is the possibility that an increased 
store of immature ADAM17 already available intracellularly will as a matter of fact 
take a longer time to become depleted, considering the fact that there is now less 
iRhom2 available following the shRNA knock-down to ensure trafficking away to the 
cell membrane. Indeed, (Figure 4.13-Middle panel) does show slightly more 
immature ADAM17 in the knock-down cells compared to their overexpressing 
variants. 
 
 
4.3.4 Phenotypic effects of increased iRhom2 
 
Over- or under-expression of iRhom2 did not appear to affect cellular proliferation. 
However, increased iRhom2 expression caused PE/CA-PJ15 cell lines to become 
slightly more spindle shaped when at low density. This phenotype may be associated 
with increased motility and was tested in scratch assays. No changes in morphology were 
observed in NOK and Liv37k cells following changes in iRhom2 expression. Increased 
rate of cell migration following upregulation of iRhom2 was observed with the PE/CA-
PJ15 and LIV37K cell lines, but not the NOK cell lines which are also non-cancerous. 
The rate of migration equally reduced with reduced iRhom2 expression following 
subsequent shRNA knock-down of RHBDF2. The fact that earlier experiments on rate 
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of proliferation showed proliferation rates remained largely unchanged following 
upregulation or indeed down-regulation of iRhom2, indicates data on migration are 
likely not influenced by changes in cell proliferation. Considering the two cancer cell 
lines, recall that the real impact of upregulation of RHBDF2 on iRhom2 protein 
expression has been earlier shown to be more marked with Liv37k cells compared to 
PE/CA-PJ15 cells. Here, comparing rates of migration between parental cells and 
over-expressing variants, there is equally a slightly more pronounced change in rate 
of migration with Liv37k cells compared to PE/CA-PJ15. Liv37k over-expressing cells 
closed completely at 0.529 X the time taken for their parental cell to close up, while 
over-expressing PE/CA-PJ15 cells took a slightly higher 0.563 X the time for their 
parental cells to close the void. This may therefore imply that iRhom2 will likely play 
a key role in tumour cell (considering there was upregulation of iRhom2 had no 
noticeable influence on rate of migration in NOK cells) migration. Whether or not the 
mature form of ADAM17 plays a role in migration as does iRhom2, at this point can 
only be speculative, considering we were unable to measure changes in mature 
ADAM17 in Liv37k cell. It does appear mature ADAM17 plays a role in migration with 
PE/CA-PJ15, but this will require confirmation with Liv37k or any other HNSCC cancer 
cell line. Of the two cancer cell lines analysed, PE/CA-PJ15 showed some measure of 
increased proliferation with upregulation of iRhom2, but this was not the case with 
LIV37K in which the trend seemed to be slightly reversed. For the non-cancer NOK 
cell lines, various strains grew in similar fashion.   
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5 DISCUSSION 
 
5.1 Introduction 
  
The experiments described in this thesis were designed primarily to investigate the 
possible roles of iRhom2 in the pathogenesis of head and neck cancers. Particular 
interest has been channelled at the sheddase, ADAM17. We have used the squamous 
cell carcinoma variants of head and neck cancers, which are known to form the vast 
majority (over 90%) of head and neck cancers in terms of histologic classifications335. 
Expression of iRhom2 and ADAM17 proteins was investigated in two cohorts of 
HNSCC tissues using Western blotting and IHC (on a previously constructed TMA)326, 
followed by correlation with clinicopathological features including recurrence and 
survival. The results obtained led to in vitro cell line work in which RHBDF2, which 
codes for iRhom2, was upregulated, and then down-regulated with shRNA knock-
down, to determine possible changes in functional characteristics such as growth and 
migration as a result of deregulation of iRhom2.     
This chapter will summarise the observations made, and discuss, limitations, 
challenges and future experiments aimed at better understanding of the role of 
iRhom2 in head and neck cancer. 
 
5.2 Summary of findings 
 
I have shown, by Western blot, that iRhom2 is often upregulated in head and neck 
squamous cell carcinomas, in comparison to adjacent normal tissues (p<0.05) and 
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that ADAM17 is also upregulated in these tissues. In particular, it should be noted 
that the levels of the immature, inactive form of ADAM17, in which the protein is 
stored in the cytoplasm are not significantly different between tumour and non-
tumour cells, but the mature form is upregulated in tumour cases. 
iRhom2 expression in oral squamous cell carcinoma correlated with survival (p<0.05), 
but not with any other clinicopathological features such as extracapsular spread, 
tumour size and recurrence.  
In in vitro studies, cancer cell proliferation was not shown to be directly influenced 
by deregulation of iRhom2, with similar growth rates being observed in wild type cells 
and their variants, over- or under-expressing iRhom2. 
However, upregulation of iRhom2 in established cancer cells increased their rate of 
2D migration in a wound healing assay, but did not confer a similar advantage to a 
non-cancerous oral epithelial cell line. 
An important finding was the observation of an increase in the level of expression of 
the mature (active) form of ADAM17, following upregulation of iRhom2 in the PE/CA-
PJ15 cells. The immature pool of the protein was also shown to be increased following 
upregulation of iRhom2.     
 
5.3 iRhom2 expression in head and neck squamous cell carcinoma 
 
It has been demonstrated previously that iRhom2, while being highly expressed by 
some tissue types such as macrophages and those involved with secretory 
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functions336, is expressed at very low levels or not at all in other tissues. It is a 
possibility that some others may either express it in very low amounts or not at all337. 
My western blot data using proteins extracted from tumour and normal tissues 
demonstrates variation in levels of expression across the two tissue types, with some 
specimens not expressing iRhom2 and others showing strong protein expression. In 
general, I noted increased expression of iRhom2 in tumour, compared with adjacent 
normal tissues. It is possible that it is not the epithelial-derived carcinoma cells that 
are expressing iRhom2 in these tissues, but that our data is due to infiltrating tumour 
associated macrophages in the cancer tissues. Data on iRhom2 expression is still 
relatively scarce, and not much has been published on iRhom2 localisation in cells. 
Zettl et al demonstrated over-expressed iRhom2 to be predominantly localised to the 
ER316, and a large pool also shown to be cell membrane localised according to Maney 
et al338. The suggestion that increased iRhom2 might originate from surrounding 
immune cells remains to be substantiated. Previous data has however shown 
increased expression of iRhom2 in macrophages328, suggesting cancer cells alone may 
not be the source of the increased measurements. To investigate this possibility, I 
undertook IHC staining of a TMA containing cores for 107 HNSCC tumours. However, 
majority of the cores stained negative for iRhom2, possibly due to the relative small 
amount of the protein in the cells. The few positive staining cores were those derived 
mainly from salivary and secretary tissues as suggested by the protein data base339. 
The lack of IHC data therefore makes it speculative to affirm that the cancer-derived 
epithelial cells are the origin of the iRhom2 expression in my western blot data. All of 
these claims will require further investigations discussed later. 
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5.4 Increased expression of iRhom2 and its effect  
 
The rhomboid protein, iRhom2 has been implicated in carcinogenesis 
previously325,340. Ongoing research keeps shedding light on the exact mechanisms by 
which this happens. Like many other signalling proteins, mechanisms of action may 
not be exactly stereotyped, but varying from cell to cell or influenced by a 
combination of other factors / associated signalling molecules. Distinct mechanisms 
/ pathways have been put forward to explain the role of iRhom2 in cancer. One has 
to do with mutation of RHBDF2, the gene which codes for iRhom2. In one study, and 
typically, it was shown that missense mutation of the RHBDF2 gene was the main 
underlying cause of Tylosis with oesophageal cancer322. Gain-of-function mutations 
in the N-terminal domains of iRhom2 have been shown to enhance the stability of 
the short-lived protein330. This increased stability may augment its function E.g. in 
EGFR signalling and maybe ADAM17 trafficking and activation, leading to cancer 
formation or progression341-343, with EGFR signalling and ADAM17 signalling already 
implicated in carcinogenesis344,345346347.  
I was able to demonstrate increased iRhom2 and ADAM17 expressions in cancer, 
using clinical tissues, though the increased expression of IRhom2 did not necessarily 
correspond with that of ADAM17. That is, some samples with increased iRhom2 
expression did not necessarily show increased ADAM17 expression. This observation 
may be due to a number of reasons. It is a possibility that the upregulated iRhom2 in 
HNSCC is channelled into other signalling pathways other than via ADAM17306,330, 
with EGF330 and Thrombomodulin306 and EphrinB3348 (both with EGF-like domain), 
already known to be substrates for iRhom2. 
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5.4.1 Upregulation of iRhom2 leads to increased expression of ADAM17 
 
Increased expression of both mature and to a lesser extent, the immature form of 
ADAM17 was observed in cell lines following upregulation of iRhom2. This is in 
keeping with published work which implicates iRhom2 in the intracellular trafficking 
of ADAM17 and therefore its activation and bioavailability for action at the cell 
membrane219,349,350. Thus, the increased expression of the mature ADAM17 in cell 
lines over-expressing RHBDF2 is likely due to increased availability of iRhom2. This is 
corroborated by the observation that shRNA knock-down of RHBDF2 in the 
overexpressing variants also produced reduced expression of mature ADAM17. 
Increased expression of the immature form was also demonstrated but was less 
marked compared to that with the mature form, raising questions as to whether the 
control of expression is both transcriptional as well as post-translational. 
Upregulation of iRhom2 caused about three-fold increment in expression of mature 
ADAM17, compared to about 60% increment for the inactive form. A lesser impact 
on the immature form is likely due to the fact that, there is already a highly detectable 
amount of the immature form (densitometry value of 52 for the immature compared 
to a value of 3 for the mature, following western blot on PE/CA-PJ15), such that 
increased availability of the trafficking protein, iRhom2, may not generate an 
overwhelming need for more immature ADAM17. The need will only probably arise 
when the immature pool is further depleted and approaches a certain baseline level 
to generate feedback. This is still speculative as there are currently no published work 
to support this hypothesis. It was observed that a sustained elevated level of the 
immature form of ADAM17 was present following shRNA knock-down of RHBDF2 in 
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the cancer cell line, PE/CA-PJ15, but not in the non-cancerous cell line, NOK. It may 
be that, the sustained levels of immature ADAM17 in the cancer cell line following 
downregulation of iRhom2 is due to unavailability of the trafficker, iRhom2, to 
deplete the pool of immature ADAM17. The level therefore remains sustained over 
time pending gradual depletion. The different observation in NOK cells may simply 
be related to the timing. The cell lines do not proliferate at the same rate, with PE/CA-
PJ15 doubling almost three times faster. There is therefore a longer time interval 
between overexpression and knock-down of RHBDF2 and harvest of the cells for 
analysis, and this may be sufficient for the NOK cells to deplete the pool of immature 
ADAM17 with its reduced levels of iRhom2. This aspect of my work validates available 
data suggestive of the influence of iRhom2 in the maturation / activation / increased 
bioavailability of ADAM17. In a study by Yang et al, and using Uncovered (hairless) 
mice to study the role of iRhom2 in hair follicle differentiation, iRhom2 mutation 
(deletion) was shown to disturb both maturation of ADAM17 and activation of 
Notch1. This lead to decreased hair proliferation as well as decreased hair shaft 
differentiation351.   
 
 
5.4.2 Effect of iRhom2 on migration. 
 
The expression of iRhom2 and ADAM17 was determined in 6 head and neck cell lines, 
4 of which were relatively low passage, and an immortalised normal oral keratinocyte 
cell line (NOK). Both PE/CA-PJ15 and PE/CA-PJ41 were shown to highly express 
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iRhom2 and the mature (active) form of ADAM17, while levels were intermediate or 
low in the low passage cancer and NOK cell lines. Upregulation of iRhom2 in two 
cancer cell lines and NOKs produced an increased rate of migration, in the form of 
wound closure, in each of the cancer cell lines that was not as obvious in the NOK 
cells. This observed increase in rate of migration is not likely due to increased 
proliferation as cell number assays did previously demonstrate that over-expression 
of iRhom2 does not alter the rate of change of cell number. Conversely, knock-down 
of iRhom2 in these over-expressing cell variants reduced migration below the wild-
type level. These data implicate activation of the iRhom2-ADAM17 pathway in the 
pathogenesis of head and neck cancers, and that this system works by influencing or 
increasing rate of cell migration. Some studies have suggested a proliferative role for 
iRhom2349,352, and this would be expected considering its role in EGFR ligand 
processing, but this is not verified by the current study. Our assay, investigating 
increased iRhom2 and its effect on cell proliferation did not show a consistent 
difference in rate of proliferation following upregulation of iRhom2. Brook et al, in 
their experiment made an attempt to outline a molecular basis for this increased 
proliferation, with a focus on iRhom2/ADAM17/EGF-family signalling. They used 
previously immortalised keratinocyte cells obtained from a male and female TOC 
patients, with already established TOC-associated iRhom2 mutation, and compared 
these with control keratinocyte cells without the TOC-associated iRhom2 mutation. 
They were able to demonstrate increased ADAM17 maturation and activity, 
represented by increased shedding of ADAM17 substrates such as TNFα, 
Amphiregulin, TGFα and HB-EGF, which were all up-regulated in the TOC keratinocyte 
cells349. The increased shedding was also shown, expectedly, to be abolished 
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following siRNA knock-down of ADAM17. The mRNA transcript levels of the listed 
ADAM17 substrates were found to be unaffected following the siRNA knock-down of 
ADAM17349, signifying a rather post-translational level of impact, thereby verifying 
functional changes due to substrate shedding and not from the gene or 
transcriptional level.    
In their experiment with hematopoietic cells, Maretzky et al, demonstrated the 
essential role of iRhom2 in the activation and substrate selectivity of ADAM17 
dependent substrate shedding352. They showed that, although the bioavailability of 
mature ADAM17 remained unaffected following iRhom2 knock-down, the available 
mature ADAM17 was unable to initiate stimulated shedding of substrates such as HB-
EGF and KitL2, but not others such as TGFα and ICAM352. 
 
 
5.4.2.1 The mechanism of cell migration 
 
Cell migration is an important multistep cellular activity, vital throughout the lifespan 
of a cell / tissues. It is important in embryonic morphogenesis, tissue repair and 
regeneration, and even in disease progression including cancer. Several molecules 
have been suggested to play key roles in cell migration, ranging from GTPases, 
kinases, cytoskeleton-modifying proteins and motor proteins353. Mechanisms of cell 
migration are generally known to be highly diverse, with the peculiar mode adopted 
by a cell / tissues depending on cell type, stage of differentiation and the nature of 
the microenvironment. The modes / mechanisms are classified as mesenchymal or 
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amoeboid in form354,355. It is equally suggested that cells may adopt a different mode 
or switch from one mode to another in response to environmental peculiarities and 
cellular changes356. The various mechanisms / modes may share a common basis, 
considering the fact that Actin, named as an important molecule for migratory 
activities is implicated in both the mesenchymal and amoeboid mechanisms357,358. It 
is believed that cells, including cancer cells establish specialised protrusive structures 
which communicate with the extracellular matrix to ensure migration. For this 
purpose, in cancer cells, EGFR has been shown to play a central role, with its 
expression shown to correlate with increased chemotactic function359. ADAMs, 
already well documented for their roles in proteolytic activities and indirect 
involvement in cell adhesion, are also implicated in tumour cell migration. Taking 
together, with iRhom2 playing a central role in the processing and activities of both 
proteins, we may be able to suggest a possible explanation to the observed increase 
in cell migration following over-expression of iRhom2 and ADAM17360. 
Our study does show that indeed iRhom2 is upregulated in HNSCC, and that this 
upregulation does bring about an increase in the rate of cell migration, but not 
necessarily proliferation or growth. We have also been able to show that there exist 
a relationship between iRhom2 and ADAM17. We conclude therefore that, iRhom2 
deregulation is implicated in carcinogenesis and suggest that the mechanism has to 
do with upregulating pathways that are directly or indirectly involved with cell 
motility. More work is required to completely unravel this, but our evidence is 
significant enough to provoke additional experiments in this line of questions.  
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5.4.3 Upregulation of iRhom2 affects cell morphology 
 
Upregulation of iRhom2 was demonstrated to produce obvious phenotypic changes 
in PE/CA-PJ15 cells, but these changes were not observed in LIV37K or NOK cells. The 
overexpressing PE/CA-PJ15 variants were found to be slightly more spindle-like in 
shape. The wild type are typically spindle-like in culture, especially noticeable when 
less confluent. The spindle-like structures appeared to be more prominent in the 
upregulated cells. 
Cells generally find themselves in multi-signalling microenvironments where several 
factors and molecules are involved in the control of their shape during migration361, 
with cell migration leading to cancer spread362. During migration, cells may change 
shape with outward protrusions towards a stimulus, especially when these are 
external (extracellular)363. The iRhom2-ADAM17 axis has been implicated in Notch 
signalling, with signalling in the form of cell-to-cell, where ligands from one cell are 
attracted and bind to transmembrane receptors of neighbouring cells184. This will 
therefore likely require the protrusion of one cell towards another to establish a 
binding complex between Notch receptors and their ligands.   
 
5.4.4 EGFR signalling and the influence of iRhom2 and ADAM17 
 
EGFR signalling and the role iRhom2 and ADAM17 play has attracted a lot of 
attention. In this study, we conclude that iRhom2 and ADAM17 are upregulated in 
head and neck cancers. We propose that upregulation of iRhom2 facilitates 
intracellular trafficking of ADAM17 thereby increasing its shedding activities on 
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signalling molecules that may be oncogenic. In cases were upregulation of ADAM17 
has not been shown to correlate with upregulation of the mature form of ADAM17, 
as demonstrated with a number of clinical tissues, the working mechanism of iRhom2 
may be via an alternative pathway such as EGFR signalling through direct regulation 
of EGF. 
 
5.4.4.1 EGFR signalling pathway 
 
In animals, vertebrates and invertebrates alike, epidermal growth factor receptor 
(EGFR/ErbB) pathway is known to play key roles in cell-cell interactions. Cell fate 
determination is one of the important roles it plays and in C.elegans and Drosophila, 
the EGFR pathway has been linked with the formation of compound eye and vulva364. 
Four layered orthologs of the EGFR pathway are known in vertebrates, participating 
in cell fate determination and cell proliferation. Mutations involving these have also 
been known to cause human cancers including head and neck cancers365. Four 
members of the ErbB lineage of proteins, namely ErbB1-4 make up the human EGFR 
family365. This group of receptors are generally structured to consist of three main 
domains, an extracellular glycosylated domain, a transmembrane domain which is 
hydrophobic, and an intracellular domain. The intracellular domain also consists of a 
juxtamembrane segment, a protein kinase part and a carboxyterminal tail365. 
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Figure 5.1 Illustration of the domain structure of the typical EGFR366  
 
 
5.4.4.2 EGFR ligands 
 
Seven ligands are known to bind to EGFR, including epidermal growth factor and 
transforming growth factor α (TGFα). The binding of ligands such as the growth factor 
to EGFR leads to an extensive conformational change which also involves the 
exposure of a dimerization arm in its extracellular domain. Following this, its 
intracellular domain also acquires a conformational change in which an asymmetric 
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homodimer, similar to that by cyclin and cyclin-dependent kinase, is formed. 
Subsequent downstream pathways targeted by this ligand-EGFR binding and 
conformational changes include, the PKB pathway (phosphatidylinositol 3-kinase / 
AKt), Ras/Raf/MEK/ERK 1/2 pathway and the phospholipase C (PLCy) pathway365 
(Figure 5.3).   
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Figure 5.2 Signalling by the ErbB/HER family: 
Signalling by the ErbB/HER family. Tyrosyl phosphorylation sites and binding partners 
are shown. The residue numbers on EGFR correspond to the mature protein, with 
those of ErbB2/3/4 corresponding to the nascent protein including the signal 
peptides365,367. 
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5.4.4.3 EGFR ligand processing and ADAM17 
 
Associated ligands are single-pass integral membrane proteins. These generally exist 
in precursor forms and are processed into secreted active forms to enable 
subsequent binding to their respective corresponding receptors. These ligand 
precursors are known to be cleaved or shed by the ADAM metalloproteases (ADAM10 
and 17)231 as part of their activation process, a posttranslational switch necessary for 
the regulation of the activities of such ligands364 (Table 5.1). Apart from ligand 
processing, the ADAMs also participate in the processing of the membrane receptors.  
 
 
Figure 5.3 Overview of ErbB family signaling: 
Overview of ErbB family signaling depicting the main downstream signaling modules. 
Adopted from Robert Roskoski365. 
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5.4.4.4 EGFR signaling and IRhom2  
 
Our study is already based on the theory that the role of iRhom2 in the pathogenesis 
of head and neck cancer is via the partnership with ADAM17 which likely leads to the 
increased shedding of notch, with subsequent effect on downstream target genes. In 
close connection with all this is the EGFR signaling pathway. On the basis of our 
results, there is a strong argument that the working hypothesis is true. The fact that 
some of our results from the use of clinical tissues did not exactly follow this trend 
means we have been forced to imagine that adjuvant and related pathways may 
exist, in which iRhom2 or iRhom2 and ADAM17 play a significant role, to ultimately 
drive carcinogenesis.  For now, the closest culprit will be the EGFR pathway. The 
rhomboid family of proteins were discovered in close connection with EGF 
signaling283 and as stated earlier, now shown to be key in the activation of EGFR. If 
indeed certain head and neck cancer tissues do not express significant amount of 
active ADAM17, in the presence of considerable iRhom2 expression, then the 
upregulated iRhom2 may be channeled into an alternative pathway independent of 
ADAM17. We suggest this may be direct interaction between iRhom2 and the EGF. 
This does not negate the fact that ADAM17 is involved with the shedding of ligands 
of EGFR, earlier highlighted.  
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Table 5.1 Ligands for ErbB family and their corresponding sheddases231,368.  
 
 
5.5 Upregulation of iRhom2 is not sufficient to initiate cancer or increase 
rate of cell migration 
 
Our study has shown that in the absence of underlying cancer, increased levels of 
iRhom2 may not necessarily confer malignant phenotype. iRhom2 was successfully 
upregulated in the non-cancer cell lines, NOK, but whereas the upregulation did 
result in increased rate of migration in the established cell lines, the NOK cells 
remained unchanged. This is understandable especially when this point is compared 
with the previous in which cell lines with the higher baseline expression of iRhom2 
did not necessarily migrate the fastest. There has to be underlying cancer for the 
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effect of upregulation of iRhom2 to be felt on rate of migration. This means that 
certain cells of the body will be safe to have a high expression of the protein and not 
become cancerous. Indeed, it has been shown that certain cells such as macrophages 
do have a high baseline expression of iRhom2, and iRhom2 has been shown to be 
upregulated in secretory cells and pathways. It is therefore likely that the increased 
iRhom2 is channelled into an already available or constituted pathway in cancer, 
which is possibly absent or in subnormal levels in normal cells. In addition, already 
established factors such as loss of cell cycle control and defects in the DNA damage 
repair mechanism, may not be related to increased iRhom2, and yet important for 
cancer to be established in cells. Again, this may be towards trafficking of ADAM17 
which has already been demonstrated to be upregulated in cancer, or indeed some 
other pathway such as the EGFR pathway. 
 
 
 
5.6 iRhom2 expression in tumour tissues correlates with patient survival. 
 
We were able to demonstrate a correlation between high iRhom2 expression on 
Western blot analysis and poor patient survival, using the Kaplan-Meier test. 
Considering data from migration experiments in section 4.2.6.2, and the suggestion 
that increased iRhom2 may be associated with increased migration in cancer cells, 
the association between poor patient survival and increased iRhom2 expression may 
therefore have everything to do with migratory regional spread. Oral cancer may not 
metastasize too frequently but spread to regional sites such as regional lymph nodes 
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does contribute to poor patient survival. Indeed, the fact that increased iRhom2 has 
not been associated with increased proliferation, following data in section 4.2.6.1, it 
will be correct to hypothesise that the associated poor patient survival is due to 
migration to regional sites rather than tumour mass expansion. Apart from 
correlation with poor patient survival, there was a lack of correlation with other 
clinicopathological factors that are also often associated with poor survival, such as 
recurrence, tumour size and extracapsular spread. This again is suggestive that the 
main morbidity factor might have to do with regional spread rather than tumour size, 
but this will require further research. A key area will be to consider the iRhom2 
protein content of tumours with nodal involvement against those without. A marked 
difference in levels of iRhom2 expression in both subsets will increase the prospect 
of improved management of oral cancer cases, with therapy targeted at iRhom2 
protein to prevent or slowdown rate of infiltration to regional lymph nodes. From the 
TMA data no correlations were observed between ADAM17 expression and 
clinicopathological data. There was no acceptable iRhom2 data from this 
methodology. It should be appreciated that the antibody used to generate the TMA 
data does not discriminate between mature (active) or immature (inactive) ADAM17, 
so we may have been assaying the immature, rather than the functional form. 
 
5.7 Future experiments 
 
Our current data has shown that iRhom2 and ADAM17 are upregulated in HNSCC and 
that upregulation of iRhom2 correlates with poor patient survival, indicating poor 
prognosis. We have also been able to show that upregulation of iRhom2 in cancer cell 
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lines leads to a higher rate of tumour cell migration, which is equally abrogated 
following downregulation of iRhom2. There is evidence from our study, that 
upregulation of iRhom2 leads to increased expression of both forms of ADAM17, 
particularly its mature form.  
Moving forward, it is important to carry out several repeats of some of the 
experiments in this study by way of validating the results obtained. There is also the 
need to extend the scope of work in an attempt to discover other signalling partners 
to iRhom2 and alternative pathways that may be involved in sustaining 
tumorigenesis. A classical alternative pathway is the EGFR pathway. Therefore, for 
future experiments, analysis of cohort of clinical samples would include probing for 
iRhom2, ADAM17 and EGF / EGFR. In that case, there would be an attempt to 
demonstrate increased EGFR signalling where ADAM17 is low, in tumour samples 
with increased IRhom2 expression. Indeed, the case might also be that there is 
increased EGFR signalling in the presence or absence of increased ADAM17. 
 
The intracellular distribution of iRhom2 and ADAM17 needs to be studied more, to 
aid understanding of intracellular movements of both proteins. There is the need to 
enlarge the cohort of clinical tissues for the part of the study involving analysis of 
tumour and their paired normal tissues, and the TMA part further optimised for 
possible positive results for iRhom2 and more specific results for ADAM17. More 
assays, particularly 3D assays, and co-culture with fibroblasts are required for 
migration and proliferation work to make them more objective.   
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5.7.1 TMA experiments 
 
Further optimisation of the TMA experiment is required. Emphasis will be towards 
being able to correctly detect iRhom2 and ADAM17. Firstly, it will be important to 
employ samples from the same patients whose tissues are also analysed on western 
blot. This way, a close correlation between both should be expected and serve as a 
means of validation of results on both sides (western blot and use of TMA). Also, very 
key will be the use of highly specific primary antibodies. Antibodies specific enough 
to select between the two forms of ADAM17 (mature and immature) when used on 
the TMA cores, and specific enough for iRhom2 (isoform 1 & 2). As earlier highlighted, 
it is expected that the mature form of ADAM17 will be localised to the cell membrane, 
while the immature pool remains cytoplasm localised. But again, this may not always 
be distinctly the case, as the mature form which obtains its maturation in the Golgi 
apparatus and get trafficked to the cell membrane may also be spotted in some 
amount in the cytoplasm before it makes its way to the cell membrane. Two sets of 
identical TMAs, separately stained with highly selective ADAM17 antibodies for the 
two forms should show different staining patterns to differentiate the two scenarios. 
For iRhom2, success will greatly depend on the quality of the antibody utilised, 
specific enough for the correct isoform, and able to detect the rather relatively 
minutely expressed iRhom2 (isoform2). 
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5.7.2 Western blot experiments with clinical tissues 
 
The clinical tissues came in varying sizes, and this is understandable as the size of 
excised tissue will depend on tumour size ab initio, and this will usually undergo 
further rationing to save portions for other forms of investigations. A good number 
of the paired normal tissues were particularly small, some too small to be used. 
Obtaining protein from tissues (unlike cells) for western blot analysis requires a 
sizeable chunk of about 5mmᵌ, as was the case in this experiment. After initial tissue 
handling to enable histology, some of the samples were no longer sufficient to have 
as much as 5mmᵌ excised from them. Equally, in some cases, the 5mmᵌ tissue was 
not sufficient to produce enough total protein to match protein from other samples 
in terms of total protein concentration. We therefore adopted a different approach 
enumerated earlier, for normalisation purposes. Moving forward therefore, it will be 
of great benefit recruiting only tissues big enough to produce enough and highly 
concentrated protein samples.  
The ratio of tumour to normal tissues needs to be as close as possible to make 
comparison fair enough in terms of frequency. The general sample size may also be 
increased to about thrice the number used in this experiment to further validate our 
findings. To make analysis as objective as possible, all protein samples may be 
extracted from tissues within a very short interval, assembled and analysed on 
western blot the same day with similar conditions. 
A large enough sample size means that there might be the possibility of assessing 
expression in tissues from a particular tumour site and have data that will be 
statistically relevant. For instance, if the entire samples size is in the range of 300, 
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there might be about 100 tongue tumour samples, in which case expression among 
tongue tissues may be effectively compared. And this will ensure correlation with 
clinicopathological data is more direct as comparison will be made against expression 
protein from tissues taken from the same sub-site. This is important, giving that 
evidence has already shown that tissues express iRhom2 in varying amounts, and that 
some tissues may not express the protein. For instance, tissues from patients, all with 
recurrence, but obtained from different sites may show different levels of iRhom2 
expression, even if the protein were possibly implicated in recurrence. This is 
because, the role iRhom2 plays may vary from cell to cell, as well as, the pathogenesis 
or molecular basis of the same squamous cell carcinoma may vary from site to site in 
the oral cavity or head and neck region. If therefore tissues from the same site, such 
as lip are analysed together and compared against clinicopathological data, there is 
that sense that the baseline expression of the protein in lip tissues are similar ab initio 
and prior to carcinogenesis. This may be verified to a large extent by the use of the 
expressing levels in the accompanying paired normal tissues. It will be considered 
worthy having greater pathological input into tissue selection, for example, if the 
tumour has infiltrating macrophages. This will help to decipher all the sources of 
iRhom2 protein following analysis. Laser capture microdissection (LCM) will also be 
considered to ensure cell specificity and equally aid investigation into source of 
protein expression. 
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5.7.3 Expanding experiment with cell lines. 
 
Our results, based on two cancer cell lines and a non-cancer cell line produced results 
that need to be further verified as the case, in two or three additional cell lines. 
Recruiting in similar fashion, one with a significant level of baseline expression of 
iRhom2, one with a moderate expression level, and a non-cancer cell line with any 
level of iRhom2 expression.  
 Probing for more partners will also open a window into understanding mechanism 
by which iRhom2 is involved with tumorigenesis. Suggested earlier, EGF or any of its 
downstream pathway products may be investigated in line with iRhom2 expression 
following deregulation of the same.  
The use of ADAM17 inhibitors such as KP-457369 to show whether ADAM17 is 
required for migration when iRhom2 is overexpressed will be considered.  
Proteomic or transcriptomic experiments on the cell lines will be useful to find out 
what other proteins are affected by upregulation of iRhom2. 
If iRhom2 is key for intracellular trafficking of ADAM17, shRNA knock-down of 
ADAM17 may produce a negative feedback to upregulate iRhom2. shRNA knock-
down of ADAM17 may therefore be looked into to further verify a working 
relationship with the two proteins. Overexpressing ADAM17 may not be of any 
significance considering the general level of expression of the immature form. It 
appears to be adequately expressed and there might be the existence of a threshold, 
above which there may be no significant difference in iRhom2 expression. It will 
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however be important to verify the level of control on ADAM17 arising from 
upregulation of iRhom2, whether transcriptional or post-translational. 
 
 
5.7.4 Migration and proliferation assays, and other functional studies. 
 
Given that some interesting and notable findings have come out of the migration 
assay of our experiment, it will be important to expand the scope by conducting 
additional functional assays such as adhesion assay and migration through a 
membrane or barrier. Examples include transmembrane assays370 and migration 
through 3D matrigel371 to depict invasion through basement membranes by OSCC 
cells. The migration assay may also be improved upon by enlisting a 3D version. This 
way, cell migration is multidirectional as the case is in vivo, therefore a more 
representative approach. Co-culture of the various cell strains with fibroblast will also 
come as an additional method to evaluate cell growth and migration. 
A proposed cell proliferation assay will involve, seeding of cells to achieve discrete 
colonies of about the same number of cells with each cell variant. That way, a regular 
count will define a precise rate of growth of cells. An animal tumorigenesis model will 
also be useful, to investigate possible increase in tumour size with nude mice, 
following iRhom2 over-expression. A similar model was used by Nicolai et al372 to 
investigate expression of αvβ3-integrins in OSCC. 
A recent study reemphasised the importance of iRhom2 for ADAM17 trafficking and 
activation. It was also demonstrated that phosphorylation of iRhom2 is required for 
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this trafficking / activation function350. Therefore for future experiments, 
phosphorylation or inhibition of phosphorylation of iRhom2 in relation to ADAM17 
expression and cell phenotype will be an important aspect to investigate.  
 
 
5.7.5 RNA analysis 
 
RNA obtained from clinical tissues may be analysed real-time to evaluate levels of 
expression. This will help to throw more light into whether or not over-expression 
effect on ADAM17 is due to transcriptional rather than post-translational effect. Like 
protein expression, data may be used for correlation with clinicopathological data. 
 
5.7.6 Effect of iRhom2 on EGF signalling  
It will be important to ascertain if iRhom2 directly controlled the levels and 
bioavailability of EGF. Just as levels of ADAM17 following up and down-regulation of 
iRhom2 was investigated, EGF levels could be measured to demonstrate direct effect. 
In this case, an important arm of the experiment would be to carry out combined 
deregulation of iRhom2 and ADAM17 to ascertain which might be of more 
importance in EGF signalling. For instance, if up and down-regulation of both proteins 
does lead to increased and decreased expression of EGF respectively, to up-regulate 
one and down regulate the other, vice versa, will likely demonstrate which of 
ADAM17 or iRhom2 does have the direct effect on EGF signalling.   
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5.8 Conclusion  
 
In conclusion therefore, we have been able to demonstrate upregulation of iRhom2 
and ADAM17 in HNSCC using clinical tissues, with increased iRhom2 expression 
correlating with poor patient survival. We have also shown that increased expression 
of iRhom2 provokes subsequent increased expression of ADAM17, particularly its 
mature form, and the resultant increased expression of iRhom2 or iRhom2 and 
ADAM17 does lead to increased cancer cell migration, independent of increased rate 
of cell proliferation. On the basis of these data, we have been able to validate the 
initial hypothesis that iRhom2 plays a role in the pathogenesis of head and neck 
squamous cell carcinomas and that this role is in partnership with ADAM17. The need 
for further experiments to reaffirm our findings has also been emphasised.       
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6 APPENDIX 1 
 
Table showing a collection of all tissue samples available for the study and their 
histology. The “use?” column indicates whether or not a sample was deemed suitable 
for the study, based on the type, size and especially tumour cell load. Of the 127 
tissue samples assessed, 95 (68 tumour and 27 normal) samples were deemed 
suitable for the study, with the remaining 28 rejected, based on their tumour cell 
population, unusable tissue type or size (too little).  
 
 
sample no. T/N Pt. No. path 1st section path last section Use? comments Additional sections
5041 T 3400 50% tumour 50% tumour y `+ inflammatory response
5042 N 3400 no tumour no tumour y salivary gland/small sections
5047 T 3401 40% tumour 30% tumour n inflammation + gland
5048 N 3401 10% tumour no tumour y keratinised tissue/ small sections
5059 T 3408 50% tumour 60% tumour y
5060 N 3408 microinvasive tumour (40%) no tumour y `+ conenctive tissue
5083 T 3412 >60% Cis? >60% Cis? y
5084 N 3412 mild dysplasia mild dysplasia y 80% connective tissue
5089 T 3413 60% tumour 50% tumour y
5090 N 3413 epithelium mild dysplasia y 80% connective tissue
5099 T 3415 salivary gland salivary gland n v. small
5100 N 3415 5% tumour no tumour y
5300 T 3421 artefactual probably 90% tumour90% tumour y small sections
5301 N 3421 no tumour no tumour y v. small
5316 T 3425 30% tumour 40% tumour n `+ inflammation
5317 N 3425 muscle muscle y
5332 T 3429 30% tumour 30% tumour n
5333 N 3429 no tumour no tumour y keratinised  
5351 no tissue no tumour ? 5356
5355 T 3440 80% tumour 80% tumour y
5359 T 3441 80% tumour 70% tumour y
5360 N 3441 muscle muscle y dysplastic epithelium
5363 T 3442 90% tumour 90% tumour y
5364 N 3442 dysplasia dyspalsia y
5367 T 3443 80% tumour 90% tumour y
5368 N 3443 no tumour no tumour n fat
5401 N 3451 no tumour no tumour y
5405 N 3452 no tumour (muslce) no tumour (muscle) y
5425 N 3449 some dysplasia; no tumour some dysplasia; no tumour y
5451 T 3458 30% tumour 50% tumour n
5452 N 3458 no tumour no tumour y
5455 T 3459 40% tumour 40% tumour n
5456 N 3459 normal gland normal gland y
5505 T 3462 90% tumour 80% tumour y
5506 N 3462 no tumour no tumour y small sections
5514 N 3464 hyperplasia; no tumour no tumour y
5603 N 3477 no tumour no tumour y
5610 T 3479 30% tumour 40% tumour n
5611 N 3479 hyperplasia; no tumour hyperplasia; no tumour y
5623 N 3482 dysplasia; no tumour no tumour y
5635 N 3485 no tissue no tissue n
5638 T 3486 40% tumour 70% tumour y
5639 N 3486 no tumour no tumour y
5654 T 3495 80% tumour 100% tumour y small sections
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5662 T 3497 10% dysplasia 10% dysplasia n `+ salivary gland/small sections
5670 T 3499 80% tumour 80% tumour y
5674 T 3500 90% tumour 85% tum y
5678 T 3501 40% tumour 60% tumour y
5694 T 3505 90% tumour 100% tumour y
5698 T 3506 60% tumour 55% tumour y
5706 T 3508 70% tumour 70% tumour y
5710 T 3509 50% tumour 60% tumour y `+ inflammation
5714 T 3510 100% tumour 100% tumour y
5718 T 3449 30% tumour 20% tumour n `+ inflammation
5840 T 3531 hyperplasia hyperplasia n small sections
5844 T 3534 20% tumour 15% tumour n `+ inflammation
5856 T 3535 95% tumour 95% tumour y
5864 T 3537 40% tumour 40% tumour n 50% muscle
5876 T 3540 100% tumour 100% tumour y
5880 T 3541 90% tumour 90% tumour y
5884 T 3542 80% tumour 70% tumour y
5892 T 3544 90% tumour 90% tumour y
5904 T 3547 50% tumour 60% tumour y
5908 T 3548 100% tumour 90% tumour y 40% highly keratinised
5940 T 3550 50% tumour (keratinized) 50% tumour y small sections
5972 T 3558 no tumour 10% tumour (mainly keratin pearls)n v small
10002 T 3566 80% tumour 70% tumour y
10010 T 3568 70% tumour 80% tumour y
10014 T 3569 mainly keratinized >90% tumour y v small
10022 T 3571 no tumour no tumour n small sections
10026 T 3572 50% tumour 50% tumour y freezing artefacts in tissue, but OK
10030 T 3573 60% tumour dysplasia & invasive carcinoma (40%)y do not use any further sections from this tissue
10034 T 3574 70% tumour 70% tumour y
10058 T 3580 80% tumour 80% tumour y small sections
10062 T 3581 v little tumour, 25% >30% tumour N small sections slice off ~10 sections and recut 1 section for H&E
10066 T 3582 50% tumour 35% tumour Y small sections do not use any further sections from this tissue
10078 T 3585 50% tumour (dyscohesive) 50% tumour y small sections
10126 T 3630 60% tumour 70% tumour y small sections
10130 T 3631 90% tumour 80% tumour y
10134 T 3632 30% tumour
no tissue
20% tumour
60% cancer
n
y (2nd set) v small slice off ~10 sections and recut 1 section for H&E

10138 T 3633 30% tumour 70% tumour y
10142 T 3634 40% tumour no tumour n v small
10154 T 3637 25% tumour 80% tumour y small sections
10158 T 3638 100% tumour 100% tumour Y
10166 T 3640 10% tumour (mixed) 10% tumour (mixed) N
10170 T 3641 40% tumour >60% tumour Y
10178 T 3643 <10% tumour <10%^ tumour N small sections
10182 T 3644 80% tumour 80% tumour Y small sections 
10190 T 3646 <10% dysplasia only mostly severere dysplasia N small sections
10194 T 3647 few cells only 30% tumour (mixed) N small sections
10206 T 3650 >60% tumour 100% tumour Y
10682 T 3661 30% tumour 100% tumour Y
10686 T 3662 >90% tumour >90% tumour Y
10698 T 3665 60% tumour 60% tumour y
10722 T 3671 100% tumour 100% tumour y 50% highly keratinised/small sections
10742 T 3676 no tumour no tumour n skin
10778 T 3685 ~30% tumour 30% tumour n freezing artefacts make assessment difficult
10790 T 3688 no tumour no tumour n v. small
10794 T 3689 no tumour no tumour n small sections
 250 
 
 
 
 
 
 
 
 
10861 T 3721 60% tumour 60% tumour y `+ salivary gland
11001 T 3701 80% tumour 60% tumour y `+ inflammation
11065 T 3717 50% tumour 65% tumour y
11069 T 3718 ~20% tumour 30% tumour n salivary gland
11073 T 3719 80% tumour 80% tumour y `+ dysplastic surface epithelium
11115 T 3723 100% tumour 80% tumour y
11123 T 3725 90% tumour 100% tumour y
11127 T 3726 100% tumour 90% tumour y extensive keratinisation
11131 T 3727 100% tumour 100% tumour y
11135 T 3728 too small >80% tumour y
11136 N 3728 no tumour no tumour y
11139 T 3729 60% tumour 70% tumour y basaloid
11140 N 3729 no tumour no tumour y
11143 T 3730 40% tumour >85% tumour y
11144 N 3730 dysplasia dysplasia y
11155 T 3415 >95% tumour >95% tumour y
11156 N 3415 no tumour dysplastic y
11167 T 3736 blood <20% N
11168 N 3736 no tumour no tumour y
11179 T 3739 70% tumour 70% tumour y fully keratinised
11180 N 3739 no tumour no tumour y
12475 T 3785 too small 25% dysplasis N
12476 N 3785 no tumour no tumour y
12479 T 3786 artefactual - can't score <10% tumour N
12480 N 3786 no tumour no section provided y muscle & salivary gland
12487 T 3788 70% tumour 80% tumour y
12488 N 3788 no tumour no tumour y
12491 T 3789 no tissue 60% tumour y basaloid
12493 N 3789 no tumour no tumour y
12504 T 3792 >70% tumour >70% tumour y basaloid
12505 N 3792 dysplastia only dysplasia  okay of this is supposed to be normal tissue - no marking on slide
12508 T 3793 <5% tumour <5% tumour N
12509 N 3793 no tumour no tumour y
12512 T 3794 70% tumour <40% tumour y
12513 N 3794 no tumour (muslce) no tumour y
12517 T 3801 >70% tumour 40% tumour y
12518 N 3801 no tumour no tumour y salivary gland
12525 T 3803 70% tumour 70% tumour y
12526 N 3803 no tumour (muscle) no section provided y
 251 
 
7 APPENDIX 2 
 
Buffers and solutions 
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8 APPENDIX 3 
 
 
Profiling of cell lines – ADAM17 expression (N-Terminal). Variable levels of ADAM17 
expression with detection of the cleaved-off low molecular weight fragment detected 
in PJ15 cell lines, but undetected in the other cell lines used.  
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